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Abstract 
In the field of tissue engineering, some of the most promising therapeutic 
applications to promote spinal cord tissue repair have involved biomaterials. Electrospun 
microfibers provide an optimum platform to both promote directional guidance and 
release a therapeutic treatment for a long-duration. Paclitaxel administration has been 
shown to promote nerve tissue repair, but translation has been limited due to its 
incorporation in a neuropathic pain-inducing solvent. This thesis describes our work in 
establishing a platform that releases microtubule-stabilizing agents (paclitaxel and 
sunitinib) from aligned, electrospun fibers to promote tissue repair after a traumatic 
central nervous system injury. 
 
 Approximately 282,000 patients in the United States have a traumatic spinal cord 
injury (SCI), resulting in a loss of function below the site of injury, and yet there remains 
no clinically approved treatment for patients after an injury. Traumatic spinal cord 
injuries ultimately result in an inhibitory environment that prevents axonal regeneration 
from occurring. Previously, a low concentration administration of paclitaxel has been 
shown to promote axonal extension and attenuate the upregulation of inhibitory 
molecules after a spinal cord injury, yet requires a new incorporation method due to 
toxicity and potency issues with a high concentration administration. Previously, aligned, 
electrospun poly-lactic acid (PLA) microfibers have promoted spinal cord tissue 
regeneration, but had a limited effect on the inhibitory components present after a spinal 
cord injury. In this study we effectively incorporated paclitaxel, and other microtubule-
stabilizing agents, into electrospun PLA microfibers and sustained their release for up to 
 ii 
twelve weeks in vitro. Additionally, we established that a local release of these molecules 
from electrospun microfibers promotes dorsal root ganglion neurite extension in a 
growth-conducive and inhibitory environment, as well as inhibits astrocytic activity such 
as proliferation and chondroitin-sulfate proteoglycan upregulation. Finally, this study 
tested this platform in a rat model of spinal cord injury and determined that it inhibits 
reactive gliosis and does not exacerbate neuropathic pain. Our findings provide a targeted 
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Tissue Engineering and Electrospun Fibers 
 
1.1 Tissue Engineering and Regenerative Medicine 
 Tissue engineering as a field refers to the usage of cells, materials, and 
biologically active molecules to enhance or replace biological tissues [1]. Due to this 
broad definition and tissue engineering’s promising applications for translational 
therapeutics, the field of tissue engineering has grown at a tremendous rate with almost 
625,000 publications mentioning tissue engineering since its inception with almost 
400,000 of those produced within the past 10 years alone [2]. To meet this demand for 
tissue engineering research, institutes and centers focused on tissue engineering, such as 
the Translational Tissue Engineering Center at the Johns Hopkins University, have been 
established across the United States. 
 
1.1.1 Cells 
The cellular based components for tissue engineering provide a platform to 
replace the damaged tissue, initiate a network, and upregulate growth-conducive factors. 
Stem cells, an undifferentiated cell type that is capable of becoming more specialized or 
producing additional stem cells, have been commonly researched for tissue engineering 
applications due to their ability to produce multiple cell types. Within the past few years, 
multiple varieties of stem cells have been discovered and produced such as induced 
pluripotent stem cells (iPSCs), which are developed without the ethical issues of other 
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stem cell types (i.e. embryonic stem cells) [3]. The usage of stem cells as therapeutic 
agents, however, has been limited due to their lack of viability after implantation, 
potential to differentiate into a carcinogenic lineage, and lack of FDA approval. 
 
 1.1.2 Materials 
In tissue engineering, materials present a scaffold for the body to integrate onto, 
stabilize the surrounding area, and direct cellular growth [4]. Materials are commonly 
used in tissue engineering applications due to their diversity, degradability, and 
established FDA-approved usages. That being said, materials must also be selectively 
chosen for each application due the host body’s immune response, toxicity of the 
material’s degradation products, and difficulty to scale up the material’s production. 
 
1.1.3 Biologically Active Molecules 
Biologically active molecules such as growth factors, hormones, and therapeutic 
molecules are needed to stimulate growth, activate a systematic response (e.g. immune), 
and even attenuate an inhibitory reaction [5]. These molecules are advantageous in tissue 
engineering usages due to their amenability (due to a concentration-dependent effect) and 
specificity; however, they can be difficult to acquire/produce and can have issues with 
loading for drug-delivery applications. 
 
1.1.4 Regenerative Medicine 
Regenerative medicine refers to the manipulating of tissue engineering concepts 
to help direct the body to repair or replace tissue [6]. Many high profile regenerative 
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medicine projects have been previously developed such as the stimulation of 
chondrocytes to form a human ear on a mouse and generating a functional heart from a 
decellularized heart implanted with autologous cells [7, 8]. Although these results have 
shown the potential direction of regenerative medicine, the field has only incrementally 
advanced within the past 20 years due to the fact that the host body regenerates poorly 
due to the activation of the immune response coupled with poor blood vessel growth and 
the fact that implanted cells do not survive in the body for an extended duration. 




 Biomaterials are substances that have been developed to interact with biological 
systems for a medical purpose – generally in a therapeutic or diagnostic capacity [9]. 
Biomaterials are commonly used in tissue engineering applications due to their ability to 
effectively mimic the native extracellular matrix (ECM), vary in size, shape, and 
dimension, as well as mimic the natural three-dimensional geometries present in vivo to 
stimulate growth and extension [10-12]. Certain applications require different types of 
biomaterials, such as using hydrogels as a drug-delivery system, functionalizing the 
surface to promote better cellular adhesion, or even improving the biodegradability of the 
material to better suit the specific therapeutic application [13-15].  
Based on their composition, biomaterials can be divided into two different 
varieties: natural substrates such as collagen, fibrin, etc. and synthetic substrates such as 
polyester polymers [9]. Both material types can be modified, loaded with a therapeutic 
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treatment, degrade in the body, and have FDA-approved therapeutic applications. 
However, natural materials lack adhesion peptides and structural strength, whereas 
synthetic polymers induce a foreign body response and can produce toxic degradation 
byproducts. For synthetic polyester polymers, these issues can be minimized by changing 
the morphology of the surface through different production techniques, functionalizing 
the surface, or incorporating molecules to attenuate the immune response [16]. 
 
1.2.1 Topographical Guidance 
Through topographical guidance, cells interact with their surroundings by direct 
adhesion to a surface, which can modulate multiple cellular activities, such as 
proliferation, migration, extension, and differentiation [17]. Varying the surface through 
variations in the porosity, functionalization of a molecule, separation distance, or fiber 
diameter can be done by various methods such as chemical etching, photolithography, 
and electrospinning [18]. In situ, cells have evolved to recognize various molecules and 
morphologies present in the ECM, such as integrins (i.e. laminin, fibrin, collagen, etc.), 
proteoglycans, and growth factors [19]. For instance, the effects of various collagen and 
laminin integrins have been extensively studied in nerve extension, regeneration, and 
function [20, 21]. This knowledge of integrin binding has been further manipulated to 
modify natural materials to mimic the natural ECM and promote cellular growth and 
tissue regeneration [10]. Furthermore, synthetic materials such as polyester polymers (i.e. 
poly-lactic acid, polycaprolactone, etc.) can regulate cellular function by functionalizing 
adhesion proteins to their surface or modifying their surface morphology [22]. For 
example, by simply varying the diameter of electrospun polymer fibers by a few hundred 
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nanometers, neuronal stem cell differentiation can be modified, neuronal extension can 
be directed and promoted, and glial cell migration speed and distance can be altered [23, 
24]. Interestingly, maximum neurite extension occurred on fibers with a diameter most 
similar to that of the axons growing directly on them as shown in Figure 1.1 [24]. 
Although topographical guidance presents multiple ways to control cellular 
function, there are some limitations. Most importantly, cells must adhere or interact with 
the surface in order to be effective, which limits the ability of the guidance to direct 
contact. Furthermore, modifying cellular function for multiple axes and dimensions is 
difficult with this system due to the surface production techniques currently available. 
Finally, this system must currently be limited to in vitro studies due to surface 
degradation, changes in the surface morphology, or blocking due to complement 
activation in vivo. 
 
1.3 Discussion 
 Fiber diameter and alignment modulates the direction and lengths of neurite 
extension, but the mechanism that drives this system remains poorly understood. The 
systems tested (as well as subsequent studies) contain a culture of mixed glial with the 
neurons as well. Although methods to mitigate these cells are used, these glia, 
specifically Schwann cells, could be modulating neuronal extension under these 
conditions. Therefore, their response should also be monitored and quantified in 






Figure 1-1: Fiber diameter and morphology modulate neurite extension 
Dorsal root ganglion neurons were cultured on aligned, electrospun poly-lactic acid fibers 
with large (A), intermediate (B), or small (C) diameter fibers for 5 days. Neurons had 
longer protrusions on the large diameter fibers (D) and better aligned to their direction as 
well (E). Scale bar: 100 µm  
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Drug Delivery Systems and Microtubule-Stabilizing Agents 
 
2.1 Drug Delivery 
Drug delivery systems involve administering molecules to the body in order to 
safely achieve a desired therapeutic effect [1]. In order to deliver an efficacious 
concentration of a drug, the quantity released and duration of the release must be 
controlled. There are various ways to control the device’s drug release, such as diffusion-
controlled, water penetration-controlled, and chemically-controlled (controlled by the 
device degradation). In a diffusion-controlled system, a first-order release is more 
common, which can lead to an initial toxic level. Water-soluble drugs work best for water 
penetration-controlled systems, which limit their therapeutic applications. For 
chemically-controlled devices, a longer duration (months-years) can be achieved. 
Among all of these drug delivery systems, non-specific targeting of treatments 
(resulting in toxicity or a lack of efficacy) and variations in drug release (due to 
variations in molecule size and uptake) can be issues. 
 
2.1.1 Targeted Drug Delivery 
 A targeted drug delivery system involves administering a higher concentration of 
a specific treatment to certain cells or tissues relative to others, which prevents non-
specific binding of the treatment and requires a lower concentration of the treatment for 
efficacy. There are two ways to administer a targeted drug delivery system: deliver 
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externally from the site of interest or locally administer the treatment to the site of injury. 
When the treatment is delivered externally, either the biology of the site of interest must 
be manipulated (i.e. via the enhanced permeability and retention effect) or the 
treatment/carrier must be modified to target the correct cells (i.e. functionalization) [2, 3]. 
However, when a local, targeted delivery is administered, there is a diminished chance of 
non-specific binding as well as the ability to bypass obstructive membranes, and 
therefore, prevent toxicity and other adverse effects [4]. 
 
2.1.2 Local Administration and Cellular Interactions 
 When a therapeutic molecule is administered locally at the treatment site, patient 
compliance increases, blood incorporation and transport is avoided, and a lower 
concentration of the molecule is needed, which results in a higher potency and fewer side 
effects. Various studies have applied this knowledge to improve the efficacy of growth 
factors for cardiomyocyte growth and nerve regeneration [5, 6]. Additionally, when a 
local release of a hydrophobic molecule occurs, the molecular uptake will vary due to the 
drug not easily dissolving in the surrounding volume, but rather be directly uptaken into 
the cell through transcellular transport or other similar techniques [7]. Furthermore, local 
administration of a treatment ensures that the therapeutic molecule binds to the targeted 
cell’s extracellular receptors, which facilitates efficacy and could result in a lower 
effective concentration needed. 
 
2.2 Therapeutic Molecules 
In treatment applications, therapeutic molecules regulate a biological process (i.e. 
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regeneration, apoptosis, growth, etc.). FDA-approved molecules have a wide range of 
sizes (from hundreds of Daltons for vitamins to thousands for hormones), specificity, and 
current therapeutic applications, but are continuously being repurposed for new 




 Paclitaxel (PTX) is a hydrophobic, mitotic inhibitor that stabilizes microtubule 
formation and is clinically administered as an anticancer agent (Taxol™) at a high 
concentration dosage (µM) for ovarian, breast, and liver cancers [8]. Mechanistically, 
paclitaxel stabilizes microtubule formation integral for cellular division, proliferation, 
and elongation through multiple signal transduction pathways such as the c-Jun N-
terminal kinase/stress-activated protein kinase (JNK/SAPK) pathway [9]. Paclitaxel 
uptake is regulated by organic anion transporting polypeptide (OATP) family members, 
which control paclitaxel’s transcellular transport [10]. In other therapeutic applications, 
such as neuronal regeneration, a low concentration administration of paclitaxel have 
shown promise [11]. However, these paclitaxel administrations must be delivered 
externally, dissolved in a toxic solvent (Kolliphor EL) due to paclitaxel’s hydrophobicity, 
and dispensed at a higher effective concentration due to cerebral spinal fluid flow [12]. 
 
2.2.2 Sunitinib 
Researchers have been investigating other potential molecules to promote 
neuronal tissue repair after an injury, such as sunitinib (STB) – another anti-cancer 
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therapeutic that blocks the dual-leucine zipper kinase (DLK) pathway and has been 
shown to promote neuronal survival [13]. Sunitinib binds to and targets the receptor 
tyrosine kinase (RTK) pathway, which regulates neuronal apoptosis and proliferation, 
among other functions [14]. However, sunitinib’s role in neuronal regeneration remains 
unknown and it’s smaller size than other therapeutics could lead to issues with its release 
from certain drug delivery systems. 
 
2.3 Electrospun PLA Microfibers 
Engineered technologies, specifically synthetic biomaterials, provide a preferred 
treatment mechanism for tissue engineering applications, because of their tunable design, 
consistent manufacturing, minimal host immune response, and ease of sterilization [15]. 
Electrospun fibers offer a molecule-loadable, biodegradable, and topographical guidance 
platform [16, 17]. Furthermore, electrospun fibers provide a flexible platform in that they 
range in size from nanometers to micrometers in diameter, can be manufactured from 
various natural and synthetic materials, and can be designed with an aligned or random-
orientation. However, electrospun fibers do not provide an adequate platform for scaling 
to a 3-dimensional cell culture model, large-scale manufacturing, and also have a limited 
material library. 
 
 2.3.1 Production 
Poly-lactic acid (PLA) was chosen as the standard polymer for this research for 
multiple reasons. To begin with, it is a biodegradable polymer that undergoes hydrolysis 
degradation. Its degradation properties can also be tuned by varying its chiral forms as 
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well as its molecular weight. Furthermore, due to its long-term FDA-approval, it has been 
extensively tested in medical devices, is easy to obtain/synthesize, and is available in 
clinical-grade varieties [18]. 
Electrospinning is a fiber-producing process in which a material (natural or 
synthetic) is incorporated in a solvent and extruded onto a grounded surface while a large 
voltage is applied. By applying the voltage to the solution, the liquid becomes charged, 
which produces an electrostatic repulsion that overcomes the original surface tension of 
the solution and results in the droplet stretching into a fiber. When this jet of charged 
particles overcomes the surface tension of the solution, it forms a conical shape, referred 
to as a Taylor cone. As the fibers are being produced from the solution, the fiber diameter 
is continually reduced as the original solvent evaporates while the fiber travels and whips 
around to the grounded collection plate [19]. In electrospinning applications, parameters 
such as the applied voltage, separation distance, and polymer concentration can be 
modified in order to produce fibers of various compositions, diameters, and orientations. 
For instance, aligned, electrospun microfibers are developed and optimized by rotating 
the grounded surface [17, 20, 21]. 
To produce electrospun PLA fibers, a modified version of the setup in Figure 2.1 
was used. Paclitaxel-loaded PLA fibers were produced by electrospinning an 8% w/w 
polymer solution of PLA (Grade 6201D, 𝑀𝑀𝑤𝑤����� = 78 kDa, 𝑀𝑀𝑛𝑛���� = 48 kDa, NatureWorks LLC, 
Minnetonka, MN), in chloroform and dimethylformamide (99:1 w/w) with increasing 
concentrations of paclitaxel (0, 0.025, 0.05, 0.1, 0.5, 1.0% w/w in reference to fiber 
weight; LC Laboratories, Woburn, MA). Sunitinib-loaded fibers were produced by 
electrospinning an 8% w/w polymer solution of PLA in chloroform and 
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dimethylformamide (99:1 w/w) with increasing concentrations of sunitinib (0, 0.025, 0.05, 
w/w in reference to fiber weight; LC Laboratories) and polyethylene glycol (0.6% and 
1.2% w/w, 𝑀𝑀𝑤𝑤����� = 200 kDa, Sigma-Aldrich, St. Louis, MO). For random-oriented fibers, 
this solution was administered from a syringe for 2 hours at a rate of 0.65 mL/hour with 
an 11 kV electrical potential applied to the needle onto a stationary, grounded surface 10 
centimeters away from the needle (Figure 2.2). For aligned fibers, this solution was 
administered from a syringe for 2 hours at a rate of 1.1 mL/hour with a 10 kV electrical 
potential applied to the needle. This solution was collected on 15-millimeter coverslips 
(Fisher Scientific, Waltham, MA) grounded to a 45-centimeter disc collector rotating at 
1450 rotations/minute (rpm) from a separation distance of 6 centimeters (Figure 2.3 and 
Figure 2.4). Although it seems like an increase in PEO resulted in a decrease in fiber 
alignment (Figure 2.4), additional modifications of this fiber production could ensure that 
this is optimized for future studies. To evaporate any residual organic solvent, the 
coverslips were placed in a fume hood overnight. Fiber morphology and alignment are 
maintained after 28 days in PBS and from sterilization by exposing the samples to 
ultraviolet radiation in a biosafety cabinet for 45 minutes as shown in Figures 2.5 and 2.6. 
Even though the fibers are biodegradable, these findings ensure that the fibers maintain 
their morphology long enough for the cells to bind and interact with them throughout in 
vitro assays and in vivo implantation. 
For in vivo applications, PLA microfiber bundles were developed. Three kilovolts 
was applied to 1 milliliter of a 12% w/w polymer solution of PLA in chloroform and 
dimethylformamide (99:1 w/w) that was extruded at 2.5 milliliters/hour twenty 
centimeters away from a 100-rpm rotating water bath. The fibers were then removed 
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from the water bath and twisted together to form a microfiber bundle with a diameter of 
~1 millimeter (Figure 2.7). All of these electrospun fiber production details have been 
summarized in Table 2.1. 
 
2.3.2 Characterization 
To determine the encapsulation efficiency of paclitaxel and sunitinib in the 
electrospun fibers, treatment-loaded fibers (1 mg) were dissolved in chloroform (1 mL). 
Then, acetonitrile/water mixture (85:15, 9 mL) was added to the solution. A nitrogen 
stream was added to evaporate the chloroform at room temperature. The resulting 
solution was then processed through an absorbance microplate reader (Molecular Devices, 
Sunnyvale, CA) at 227 nm and 431 nm for sunitinib, and maximum absorbance was 
quantified. 
Fiber micrographs were acquired using a field-emission scanning electron 
microscope (SEM, JEOL 6700F) and fiber diameter and alignment were quantified using 
the Image J software (US National Institutes of Health, Bethesda, MD). These values 
were then averaged per sample (n = 100/group). 
In order to first develop a platform that could sustain an extended treatment 
release, paclitaxel was incorporated into the polymer solution at an expected loading 
concentration, assuming a 100% loading efficiency, from 0 – 5% (mass paclitaxel/mass 
microfiber). Due to some of the paclitaxel binding to the vials and some not being 
completely incorporated in the fibers, approximately 40–65% of the paclitaxel was 
actually loaded in the microfibers (Table 2.2). Furthermore, the fiber diameter remained 
between 1.37–1.51 µm for all paclitaxel incorporation groups and median fiber alignment 
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was quantified between 2–8 degrees for aligned microfibers (Table 2.2). Neither 
paclitaxel nor sunitinib incorporation into aligned microfibers altered the diameter or 
alignment of these fibers. 
Therapeutic molecule incorporation efficiency was determined by dissolving the 
electrospun microfibers into an organic solvent solution (85% acetonitrile: 15% water) 
and processing them through an ultraviolet detector, and maximum absorbance was 
quantified for each sample (Table 2.2). Paclitaxel incorporation was determined to be 39–
65% for groups with an expected loading level of paclitaxel from 0.05–5.0%, 
respectively. For fibers incorporated with 0–5% sunitinib, the loading efficiency was 
determined to range from 70–30%, respectively. One caveat of this loading methodology, 
however, is that the consistency of the treatment in the fibers is unknown. Therefore, 
before preparing the fibers the polymer solution was mixed for approximately 30 seconds 
in order to attempt to evenly distribute the treatment throughout the solution. 
The release of paclitaxel and sunitinib from the fibers was determined by placing 
coverslips of paclitaxel-loaded fibers (1.5 mg) in PBS (500 mL) and obtaining aliquots of 
the solution once every three days. These samples were analyzed by high-performance 
liquid chromatography (HPLC; Waters, Milford, MA) with a mixture of acetonitrile and 
water (85:15, v/v) as the mobile phase. Fifty microliters of the samples were passed in the 
mobile phase through a C-18 column (Agilent Technologies, Santa Clara, CA) at a rate of 
1 mL/min. The column effluent was detected at 227 nm or 431 nm using an ultraviolet 
detector for detection of paclitaxel or sunitinib, respectively.  
Release rate and duration of paclitaxel and sunitinib were quantified by 
submerging 1.5 mg of electrospun microfibers into 500 mL of phosphate buffer solution 
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at 37ºC for 84 days and 14 days, respectively. Biweekly aliquots of the supernatant were 
removed and processed by HPLC for each sample (n = 3). The cumulative release of 
paclitaxel from electrospun microfibers was well maintained over 84 days in the higher 
expected loading level groups (0.02–3.26%; Figure 2.8). Paclitaxel release from the 
microfibers is inversely correlated to the percent release of paclitaxel depending on the 
loading-level of paclitaxel in the microfibers. As such, 7–97% of the paclitaxel loaded 
into the fibers was released from the microfibers with a paclitaxel loading between 3.26–
0.02% paclitaxel, respectively (Figure 2.8). 
In order to translate this microfiber platform to an in vivo model of spinal cord 
injury, a conduit or bundle of microfibers was used. Before this bundle can be used, 
though, its release characteristics must be compared to that of the individual microfibers. 
In Figure 2.9, one-milligram of this bundle is shown to release paclitaxel at a higher rate 
and concentration than the previously produced individual fibers when compared to the 
same weight of fibers for both groups. However, a major advantage of this entire 
platform is its tunable capabilities, so a lower concentration of paclitaxel could instead be 
used for additional in vivo studies. 
In addition, sunitinib release was characterized for 14 days in a phosphate buffer 
solution. Originally, sunitinib release was limited among all groups (Figure 2.10), but 
polyethylene glycol (PEG/PEO) was added to weaken the bond between the hydrophobic 
polymer (PLA) and the hydrophobic treatment (sunitinib) as well as increasing the 
porosity of the fibers to promote more sunitinib release [22]. Once the PEO was added to 
the fibers at 0.6 or 1.2% w/v, the release of sunitinib increased approximately 500 fold 
(Figure 2.10) to a level consistent with previous therapeutic concentrations [13]. 
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2.4 Conclusions 
We have developed a platform that controls the release of molecules from a 
variety of electrospun fiber types, which allows this system to be easily translated and 
modified for multiple therapeutic applications. Electrospun fibers provide an ideal 
conduit to promote tissue engineering through contact guidance and the ability to release 
treatments over a prolonged period of time. In this study, we have shown that we can 
produce electrospun fibers that can be loaded with and release paclitaxel and sunitinib 
from 12 weeks to a minimum of 2 weeks, respectively. Furthermore, incorporating these 
molecules and using our current sterilization technique do not modify the fiber diameter, 






Figure 2-1: Electrospinning setup for producing aligned microfibers 
In order to produce aligned, electrospun microfibers, a voltage (kV) is produced and 




Figure 2-2: SEM micrograph of random-oriented PLA fibers.  
Random-oriented PLA fibers were produced by electrospinning PLA onto a grounded, 
immobile surface. Scale bar: 5 µm  
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Figure 2-3: SEM micrographs of aligned, electrospun paclitaxel-loaded PLA fibers 
Incorporating paclitaxel in electrospun PLA microfibers does not alter fiber morphology, 
diameter, or alignment. Aligned PLA microfibers were produced by electrospinning a 
PLA solution with increasing expected concentrations of paclitaxel 0% (A), 0.05% (B), 
0.1% (C), 0.5% (D), 1.0% (E), 5.0% (F) (w/w 1 milligram of PLA) and visualized by 
scanning electron microscopy. Scale bar: 5 µm. 
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Figure 2-4: SEM micrographs of aligned, electrospun sunitinib-loaded PLA fibers 
Incorporating sunitinib in electrospun PLA microfibers does not alter fiber morphology 
or diameter. Sunitinib was loaded in PLA fibers at increasing concentrations (0–5%) with 
two concentrations of PEO (0.6% and 1.2%) and visualized by scanning electron 
microscopy. Scale bar: 10 µm.  
PLA-0.6% PEO PLA-5% STB-0.6% 
PEO 




Figure 2-5: Sterilization by UV light does not affect fiber morphology 
After 45 minutes of sterilization in a biosafety cabinet, electrospun microfibers did not 
lose their morphology or experience a significant variation in fiber diameter as shown by 
the micrographs taken by a scanning electron microscope. Scale bar: 5 µm 
  




Figure 2-6: Fiber degradation observed after 28d in in PBS 
Fibers retain their morphology after 28 days in PBS. Pores are beginning to enlarge in 
some of the fibers, but overall the fibers retain their morphology and alignment after 28 




Figure 2-7: SEM micrographs of PLA microfiber bundles 
Electrospun microfibers were developed using a water-based electrospinning process as 


































































(µm ± STD) 
Fiber 
Alignment 
(º ± STD) 
0 (PLA) N/A 0 1.41 ± 0.29 4.79 ± 4.36 
0.05 39.4 0.0197 1.56 ± 0.45 3.21 ± 2.47 
0.1 42.4 0.0424 1.39 ± 0.37 7.56 ± 6.84 
0.5 50.7 0.254 1.50 ± 0.51 6.32 ± 3.83 
1.0 58.2 0.582 1.36 ± 0.43 2.32 ± 1.99 
5.0 65.2 3.261 1.44 ± 0.41 4.45 ± 4.16 
 




Figure 2-8: Paclitaxel release from electrospun fibers 
Paclitaxel release from PLA microfibers can be controlled and tuned based on the 
original loading level of paclitaxel. PLA microfibers were placed in PBS and aliquots 
were analyzed by HPLC over 84 days and the cumulative (A) and fraction (B) release 
were calculated. As the initial loading of paclitaxel increased, the release rate increased, 
and the fraction released increased at a slower rate than fibers with a lower incorporation 




Figure 2-9: Paclitaxel release from microfiber bundles 
Larger diameter PLA fibers release paclitaxel faster than smaller diameter fibers. 
Paclitaxel release from electrospun PLA electrospun fibers (left) releases slower than 
similar paclitaxel loadings in fiber bundles (right). Both groups show a concentration-
dependent effect with a higher loading of paclitaxel resulting in a faster release and larger 




Figure 2-10: Sunitinib release from electrospun fibers 
Sunitinib release from PLA microfibers occurs faster with a polyethylene glycol 
incorporation. Originally, sunitinib was loaded in PLA fibers with the same incorporation 
technique as paclitaxel. However, minimal sunitinib was released over 25 days of release 
(top). After incorporation with PEG (0.6% and 1.2%), sunitinib released at a faster rate 
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Chapter 3 




 Physical trauma occurs and is characterized by an external force impacting the 
body causing an injury or dysfunction. These medical maladies are unique due to the 
inability to eliminate them; instead, they can only be treated by mitigating their 
occurrence through safety measures (seatbelts, helmets, etc.), reducing the complications, 
and treating the results afterwards [1]. 
 
3.1.1 Neuroregeneration 
 Nervous system tissue degeneration generally occurs after a traumatic injury 
physically severs an axon or in degenerative disorders such as Alzheimer’s or Guillain–
Barré syndrome where the neuron slowly degrades over time. Neuroregeneration presents 
a way for nerves to regrow or repair after issues are initiated to prevent further damage to 
the surrounding tissue and downstream targets [2]. Neuroregeneration can further be 
classified into peripheral nervous system regeneration (PNS) and central nervous system 
(CNS) regeneration. PNS regeneration is localized to the nervous system outside of the 
brain and spinal cord. Damaged PNS nerves regenerate at a slow rate (~1mm/day), but 
have a modestly growth conducive environment due to assistance and stimulation from 
the surrounding glial cells, such as Schwann cells [3]. CNS regeneration, which is 
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localized to the brain and spinal cord, however, does not readily occur due to the 
inhibitory environment present after an injury, primarily comprised of glial cell, which 
can lead axonal degeneration. 
 
3.1.2 Spinal Cord Injury 
Spinal cord injuries (SCIs) are traumatic injuries that occur to the spinal cord. 
SCIs currently affect approximately 282,000 patients with an additional 17,000 new cases 
each year in the US alone [4]. SCIs typically result in functional deficiencies below the 
site of injury such as a loss of bladder and locomotor control. Biologically, an SCI is 
characterized by an initial, physical insult (primary injury) followed by a secondary, 
deleterious cascade (secondary injury) that culminates in the formation of a cystic cavity 
lined by a primarily astrocytic scar (reactive gliosis) [5, 6]. Additional inhibitory factors 
present or upregulated after a spinal cord injury such as myelin debris and the lack of a 
growth permissive scaffold prevent axonal extension from occurring as shown in Figure 
3.1 [7]. Nerves can regenerate across the lesion site but need additional growth-
promoting or sustaining factors, such as directional guidance and growth factors, to 
facilitate this process [8]. For the past ten years, clinical treatments for SCIs have 
involved the off-label usage of an acute administration of methylprednisolone, a steroid 
that prevents inflammation [9]. However, due to a lack of clinical efficacy and an 
increased risk of infections, new treatments for SCI patients must be further developed 




3.1.3 Therapeutic Molecules for Nerve Regeneration 
Systemic drug delivery approaches have limited access to the spinal cord due to 
the limited diffusion through the blood spinal cord barrier (BSCB) [12]. Initial solutions 
to circumvent this issue have involved locally administering biological treatments such as 
stem cells, peripheral nerves, and Schwann cells although limited cell survival and host 
tissue regeneration have been observed [13-16]. Due to these limited results, various 
engineered drug delivery methodologies such as hydrogels [17], nanoparticles [18], and 
foam scaffolds [19] have been developed. By administering these treatments loaded with 
hydrophilic neurotrophic growth factors or anti-inflammatory modulators locally at the 
injury site, issues such as non-specific binding, toxicity, and the need for a second 
surgery for treatment implantation can be avoided [20, 21]. In order to advance the 
capability of a local administration to promote spinal cord tissue repair, additional 
treatments, specifically hydrophobic treatments, must be established. 
For axonal formation and extension, microtubule stabilization must occur to 
prevent the rapid depolymerization of microtubules after axotomy [22-24]. Previous 
research has been conducted to broaden the knowledge of axonal extension and the role 
of microtubule stabilization in this process [25, 26]. In the past few years, one of the most 
promising microtubule-stabilizing agents used for SCI repair has been paclitaxel. In fact, 
a low concentration administration of paclitaxel has been shown to promote axonal 
extension in vitro [23] as well as mitigate the production of inhibitory molecules by the 
glial scar in vivo [27]. However, previous delivery systems have been limited due to 
paclitaxel’s poor solubility, non-specific binding, and its large size preventing penetration 
through the BSCB [28]. Additionally, its poor solubility requires that it be administered 
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in a toxic solvent, Kolliphor EL, that induces neuropathy [29]. One study attenuated these 
issues by delivering paclitaxel locally via an osmotic mini-pump [27]. However, the 
mini-pump still requires paclitaxel to be administered in Kolliphor EL and can also be 
dislodged, induce infections, and has a limited loading capacity. 
Another therapeutic that has shown promise in nerve regeneration is sunitinib 
(STB). Unlike paclitaxel, sunitinib is less hydrophobic than paclitaxel, which means that 
it can be incorporated at a higher concentration, has a smaller molar mass, and longer 
half-life, which all can lead to a faster and longer administration. As previously 
mentioned this anticancer drug stabilizes microtubules, a process necessary for axonal 
extension. When delivered at low concentrations, sunitinib has previously been shown to 
induce microtubule stabilization through the nuclear factor-kappa B (NF-κB) signaling 
pathway, which increases neuronal survival and prevents neuronal cell death in a dose-
dependent manner [30, 31]. Based on a patent by the Zack lab at the Johns Hopkins 
University, the most efficacious doses of STB on retinal ganglion cells for neurite 
extension in vitro were found to be between 0.5 and 1.0 μM [30]. For both paclitaxel and 
sunitinib, a better delivery mechanism is needed to effectively release the molecules for 
an extended duration, and control their release to ensure that a minimum effective dosage 
is administered while preventing toxicity (through high concentration administrations), as 
well as avoid the use of toxic solvents for administration. 
 
3.1.4 Role of Electrospun Fibers in Nerve Regeneration 
As previously mentioned, electrospun fibers have been shown to provide a 
directional guidance that enhances axonal extension in vitro (Figure 1.1) [32] and 
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decrease the cystic cavity volume in vivo [33]. However, these microfibers do not have a 
direct effect on the inhibitory environment that is present after a traumatic nerve injury 
occurs. Previous approaches to improve spinal cord tissue repair with aligned microfibers 
or paclitaxel haven seen limited results by only targeting a subset of the issues associated 
with an SCI. Therefore, incorporating another system or loading a molecule, such as 
paclitaxel, in the fibers to attenuate this inhibitory response could promote neuronal 
regeneration after an SCI occurs. 
 
3.2 Methods 
 3.2.1 PLA Spin Coating 
Glass coverslips were coated with an approximately 50-micron layer of PLA by 
placing 20 microliters of an 8% w/w PLA solution in chloroform: dimethylformamide 
(Sigma-Aldrich, 99:1, w/w) on a spin-coater (Laurell, North Wales, PA) for 
approximately 30 seconds until the surface is evenly-coated. 
 
3.2.2 Retinal Ganglion Cell Isolation and Culture 
All of the following animal procedures were conducted in accordance with 
protocols approved by the Institutional Animal Care and Use Committee (IACUC) at The 
Johns Hopkins University. Retinal ganglion cells (RGCs) were derived from human 
embryonic stem cells (hESCs) as described previously [34]. Once these cells were 
produced, hESCs were incubated in TrypLE (Life Technologies, Carlsbad, CA) for one 
minute and transferred into DMEM/F12 (Gibco), and centrifuged for six minutes at 
150 × g. This cell pellet was then dissociated via gentle pipetting in N2B27 differentiation 
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media [1:1 mix of DMEM/F12 and Neurobasal media (Life Technologies) with 1x 
GlutaMAX Supplement (Life Technologies), Antibiotic-Antimycotic (Invitrogen, 
Carlsbad, CA), N2 Supplement (Life Technologies), and B27 Supplement (Life 
Technologies)]. The cell clump suspension was then placed onto aligned PLA 
microfibers with increasing concentrations of paclitaxel (0, 0.02, and 0.58%) coated with 
1% Matrigel (Corning Life Sciences, Corning, NY) for 1 hour and cultured for fifteen 
days in NB27 media. 
 
3.2.3 DRG Explant Extraction 
Dorsal root ganglion (DRG) neurons were extracted from P5 Sprague Dawley rat 
pups (Charles River, Wilmington, MA) and split in half and placed on either poly(L-
lysine) (100 mg/ml, Sigma-Aldrich) and laminin-coated (10 µg/mL, Invitrogen) film, 
random-oriented fibers, or aligned fiber samples. Approximately two explants were 
placed on each sample for five days in neurobasal medium (Invitrogen) with B-27 
supplement, L-glutamine, and penicillin-streptomycin. 
 
3.2.4 DRG Isolation 
DRG neurons were isolated from P5 Sprague Dawley rat pups (Charles River, 
Wilmington, MA) and enzymatically digested in 0.1% collagenase type I (Sigma-
Aldrich) for 30 min and then in 0.25% trypsin (Invitrogen) for 45 min at 37ºC. Enzymatic 
digestion was stopped by adding trypsin neutralizing solution (Invitrogen), and cells were 
recovered with centrifugation for 8 min at 1000 rpm at 4ºC. Dissociated neurons were 
filtered through a 40-µm filter onto poly(L-lysine) and laminin-coated film, random-
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oriented, or aligned fiber samples for five days in neurobasal medium with B-27 
supplement, L-glutamine, and penicillin-streptomycin (P/S). This medium was 
supplemented with decreasing concentrations of Cytarabine (Sigma-Aldrich) and NGF 
(Invitrogen). Cells were seeded at a density of 7,500 cells/cm2.  
 
3.2.5 Transwell Culture with CellCrown™ Inserts 
Sheets of random-oriented PLA microfibers (2 mg) with and without paclitaxel 
were incorporated into CellCrowns™ (Scaffdex Ltd., Tampere, Finland) according to the 
manufacture’s instructions. These CellCrowns™ were then placed over the cultured DRG 
neurons growing directly on tissue culture polystyrene (TCPS) or aligned PLA 
microfibers without paclitaxel. 
 
3.2.6 Nocodazole 
To assess the mechanism of neurite extension, some of the media for the groups 
was supplemented with Nocodazole (250 nM, Sigma-Aldrich) at 6 – 24 h after cell 
seeding. Various concentrations of nocodazole (75 nM – 500nM) were used to determine 
the concentration that allowed neurite extension to occur but was diminished from the 
previous control groups. 
 
3.2.7 Neuronal Survival Assay 
In order to determine the effect of paclitaxel on neuronal survival, an alamarBlue 
survival assay was used. Four hundred microliters of a ten percent alamarBlue 
(Invitrogen) in DRG media solution was added to isolated DRG neurons cultured at 
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20,000 cells/cm2 on TCPS or aligned PLA microfibers with 0, 0.02, or 0.58% paclitaxel. 
After 4 hours of incubation, the plates were exposed to an excitation wavelength of 540 
nm, and the emission of 590 nm was recorded in a plate reader (Biotek, Winooski, VT), 




In order to visualize the cells, neurons were blocked with antibodies against 
neuronal specific markers. Cells were fixed for 1 hour with 4% paraformaldehyde (PFA, 
Electron Microscopy Sciences, Hatfield, PA) and blocked in PBS-5% normal goat serum 
(Sigma-Aldrich) and 0.1% Triton-X (Sigma-Aldrich). DRG cells were incubated 
overnight at 4ºC with a chicken anti-neurofilament antibody (NF, 1:1000, Millipore, 
Temecula, CA). Specimens were subsequently incubated for 1 hour with goat anti-
chicken Alexa Fluor® 488-conjugated secondary antibody (1:300, Life Technologies) 
and cover-slipped with Fluoroshield™ mounting medium (Sigma-Aldrich). 
 
3.2.9 Imaging 
 Micrographs were acquired after the neurons were cultured for five days using 
bright field and confocal microscopes (Carl Zeiss, Inc., Oberkochen, Germany). The 
neurons were imaged using the 5x, 10x, and 20x objectives in the 358 (DAPI), 488, or 




3.2.10 Quantitative Analysis 
Using the ImageJ software, neurite extension was quantified by outlining the 
length from the edge of the soma to the end of the neurite for each neurite per neuron. 
These values were then averaged per well (n = 50 cells/group). Data are shown as mean ± 
standard error of the mean (SEM), and were analyzed using Matlab® (Mathworks, 
Natick, MA). The experiments involving a single determination of means between two 
independent groups were analyzed with the Student’s t-test or the one-way analysis of 
variance (ANOVA). Statistical significance was set at p < 0.05 unless otherwise noted. 
 
3.3 Results 
 3.3.1 Effect of a Local PTX Release on Neuronal Survival 
Previous studies have shown that paclitaxel administration can induce neuropathy 
and neuronal toxicity. Therefore, in order to assess the survival of DRG neurons after five 
days in culture, an alamarBlue Cell Viability Assay was conducted. Isolated DRG 
neurons were cultured on either TCPS or PLA microfibers with increasing concentrations 
of paclitaxel (0, 0.02, 0.58%). Measuring the fluorescence of the samples periodically 
over five days yielded no significant difference between the normalized activities 
between the paclitaxel-loaded groups. (Figure 3.2). Therefore, paclitaxel release from 
PLA microfibers does not inhibit neuronal survival after five days in vitro and concerns 




3.3.2 Retinal Ganglion Cell Response to a Local Release of PTX 
In order to determine the effect of a local release of paclitaxel has on various 
central nervous system neuronal extension, retinal ganglion cells (RGCs) derived from 
human embryonic stem cells (hESCs) were cultured on PLA microfibers with PTX 
loadings of 0, 0.02, and 0.58% for fifteen days. Although a local release of paclitaxel did 
not have a stimulatory effect on RGC extension, it did not have a negative effect on RGC 
extension (Figure 3.3). 
 
3.3.3 Neuronal Extension on Aligned PTX-loaded PLA Fibers 
To establish that paclitaxel retains its activity after incorporation into microfibers 
and the effect of this local release mechanism on neuronal extension, dorsal root ganglion 
(DRG) neuron explants and isolated neurons were harvested from P5 rat pups and 
cultured for five days on aligned electrospun microfibers with increasing concentrations 
of incorporated paclitaxel. Importantly, paclitaxel released from the aligned microfibers 
modulated neurite extension in both isolated and explanted DRG neurons (Figure 3.4 and 
Figure 3.5). Furthermore, this extension occurred in a paclitaxel concentration-dependent 
manner. As the concentration of paclitaxel increased, neurite extension was hindered due 
to an over-stabilization of microtubules (Figure 3.4D). However, lower concentrations of 
paclitaxel (0.02% PTX/PLA fiber, w/w) promoted a greater and faster extension of 
neurites in both isolated and explanted DRGs than PLA fibers alone (p < 0.01) as shown 




3.3.4 Cell Crowns to Determine Effect of Local PTX Release 
 In order to determine the necessity of a local release of paclitaxel from 
electrospun microfibers directly in contact with extending axons, sheets of microfibers 
loaded with various concentrations of paclitaxel were placed in CellCrown™ inserts in 
cell culture media approximately 5 mm above isolated DRG neurons (Figure 3.6A). 
DRGs were simultaneously cultured directly on either TCPS, aligned PLA microfibers, 
or paclitaxel-loaded aligned microfibers. Released paclitaxel from microfibers placed in 
the inserts does not significantly promote neurite extension when neurons are cultured on 
TCPS or aligned PLA microfibers (Figure 3.6D). Additionally, cells cultured directly on 
paclitaxel-releasing aligned microfibers induced maximum neurite extension, as shown in 
Figure 3.6D. 
 
3.3.5 PLA Topography Determines Neurite Extension 
 To examine the importance of the surface topography and alignment of a PLA 
substrate, DRG neurons were cultured on paclitaxel-incorporated spin-coated thin films 
and random-oriented microfibers. In order to determine the importance of the fiber 
alignment, a random microfiber orientation was constructed by electrospinning a PLA 
solution onto a stationary, grounded surface. As an additional control and to determine 
the importance of the fiber morphology to neurite extension, a PLA thin film was casted 
onto glass coverslips with an approximate thickness of 50 microns. Isolated DRG 
neurons were cultured on paclitaxel-loaded random-oriented microfibers and films 
(Figure 3.7A-D). This local release of paclitaxel enhanced neurite extension, but not 
significantly more than films and random-oriented fibers without paclitaxel (Figure 3.7E). 
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These results confirm that a local release of paclitaxel from aligned PLA microfibers was 
most effective to promote neurite extension (Figure 3.7E). Thus a local release of 
paclitaxel coupled with and from an aligned microfiber matrix is necessary to promote 
neurite extension in a synergistic and concentration-dependent manner. 
 
3.3.6 Nocodazole Administration to Determine Mechanism of Action  
 Low concentrations of paclitaxel have been shown to induce microtubule 
stabilization in order to maintain axonal extension. In order to ensure that a local release 
of paclitaxel does not induce a novel neurite extension mechanism, 250 nM of 
nocodazole, a molecule that destabilizes microtubule formation, was added to isolated 
DRG neurons cultured on PLA microfibers with and without paclitaxel. After five days 
of culture the neurite extension that was previously seen due to a local release of 
paclitaxel was abolished and there was no significant difference in neurite extension 
among the groups (Figure 3.8). Because this effect is ablated after the introduction of 
nocodazole, a local release of paclitaxel has been shown to, at least, stabilize microtubule 
formation and axonal extension, by activating the DLK pathway. 
 
3.3.7 Effect of a Local Release of Sunitinib on Neuronal Extension 
 Although the importance of paclitaxel release from aligned microfibers has been 
shown, sunitinib provides a smaller and less hydrophobic molecule, which could lead to a 
faster diffusion and better incorporation efficiency as a potential therapeutic for spinal 
cord injury applications. In order to facilitate this process, PEO was added to promote 
STB release from the electrospun fibers. In this study, we plated isolated DRG neurons 
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on top of aligned PLA microfiber with increasing concentrations of STB (0–0.5%) and 
two concentrations of PEO (0.6% and 1.2% w/w). When 0.6% PEO was incorporated in 
the fibers, neurite extension increased when STB was included and plateaus at 0.5% STB 
incorporation (Figure 3.9). However, when 1.2% PEO was added to the fibers, neurite 
extension significantly increased with the 0.05% STB-loaded group, but decreased 
(compared to the 0.05% STB group) in the 0.5% STB-loading group (Figure 3.10). Even 
with this decrease, though, the 0.5% STB-loaded group still had a significant increase in 
neurite extension compared to the aligned PLA microfiber group (0% STB), suggesting 




Initial testing to determine the effect of paclitaxel on neurite extension involved 
culturing mature retinal ganglion cells for fifteen days on fibers with increasing 
concentrations of paclitaxel. Although no significant difference in extension was 
observed, inhibition of neurite extension was not observed suggesting that that particular 
concentration of paclitaxel does not have an inhibitory effect on RGC extension. 
Furthermore, RGC growth may not have occurred due to a mixed culture with glia, 
because differentiated RGCs may still maintain some glial or proliferating cell 
morphology, or paclitaxel release could maybe not be effective on RGC nerve growth as 
other neuronal subtypes [35]. 
As an additional platform for nerve regeneration applications, SCI axonal 
extension is limited due to the upregulation and migration of inhibitory factors and cells 
45 
to the site of injury [36, 37]. In this study, we demonstrate that a local release of 
paclitaxel or sunitinib from electrospun fibers, in a concentration-dependent manner, 
remains active to promote neurite extension after release by stabilizing microtubule 
formation in neurons. Additionally, this therapeutic release from microfibers can be 
controlled and tuned for both molecules. Furthermore, incorporated paclitaxel in PLA 
microfibers can maintain neuronal survival and promote neurite extension under growth-
conducive conditions (laminin-coated surfaces). 
In addition, paclitaxel incorporated into electrospun microfibers remained active 
in promoting axonal extension. To establish this, we used a well-characterized model of 
neurite extension with isolated dorsal root ganglion neurons cultured on approximately 1-
milligram of PLA microfibers loaded with various concentrations of paclitaxel. We found 
that this administration technique retained paclitaxel’s axon extension modulation in a 
concentration-dependent and synergistic effect. By removing this direct release to cells, 
axons lost their ability to maintain their extensions. We hypothesize that this effect was 
due to a lack of an efficacious paclitaxel concentration present in the entire well, which 
can initially be compared to that seen in lower paclitaxel (0.025%) incorporation group 
(not pictured). Even with the same PLA polymer solution, if the DRG neurons were 
cultured on this solution (film) or with a similar topography (random fiber), the local 
release of paclitaxel only slightly increased axonal extension, but not significantly. We 
hypothesize that this synergistic effect is due to the aligned fibers promoting axonal 
elongation coupled with the local release of paclitaxel that further maintains these 
extensions to maximize axonal growth. Only the local release coupled with the 
directional guidance benefits of aligned microfibers promoted neurite extension under 
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these conditions showing that this synergistic effect is necessary for maximum neurite 
extension. 
Microtubule stabilization is integral for axonal polarization, extension, and 
formation during neurite development as well as after an axotomy [22, 23, 38, 39]. 
Throughout axonal elongation, various intracellular components such as microtubules 
regulate the direction and formation of growth cones [40, 41]. Paclitaxel prevents the 
formation of retraction bulbs after a lesion by polymerizing and stabilizing disorganized 
microtubules into an aligned morphology [42]. However, paclitaxel administration must 
be controlled to prevent neurite growth inhibition by an over-stabilization of 
microtubules [39] as well as prevent neuronal toxicity [43]. This study mitigates these 
concerns by administering paclitaxel at lower concentrations than those used in previous 
studies [33]. 
Considering the results seen with paclitaxel, other microtubule-stabilizing 
molecules, such as sunitinib were incorporated into aligned PLA microfibers. Initial 
incorporations of STB showed minimal release and effect on neurite extension (Data Not 
Shown). However, PEO was added at 0.6% and 1.2% w/w in order to facilitate STB 
release and increase PLA microfiber porosity. When 0.6% PEO was added to the fibers, 
we hypothesize that a similar amount of STB is released between the same groups so no 
difference in neurite extension is observed. Therefore, an increase in STB incorporation 
could potentially lead to longer neurite extensions. In the 1.2% PEO group, we 
hypothesize that a higher concentration of STB is released from the fibers, which leads to 




Although preliminary studies have established that paclitaxel can promote neurite 
extension at low concentrations, we have shown the necessity of paclitaxel release from 
aligned, electrospun microfibers to promote neurite extension under these conditions. 
Furthermore, we showed for the first time that sunitinib has an effect on and promotes 
neuronal extension. Moreover, these studies have demonstrated the requirement of both a 
growth-promoting scaffold and a microtubule-stabilizing agent to promote a synergistic 
effect that maximally promotes neurite extension and maintains neuronal survival. 
Overall, we established that paclitaxel and sunitinib remain active after incorporation into 
PLA electrospun microfibers. The release of both therapeutic molecules from these fibers 
is controllable and tunable for a prolonged period of time. The coupling of this release 
from aligned fibers enhances a greater neurite extension than either component alone 
under growth-conducive environment. Our findings show that aligned, electrospun 
microfibers incorporated with a low concentration of paclitaxel can provide a versatile, 
controllable, and readily tunable administration technique to provide a local, sustained, 
and tunable delivery mechanism for therapeutic applications after a traumatic spinal cord 
injury to promote neuronal regrowth. Although this platform had a modest effect on RGC 





Figure 3-1: Biological response to a spinal cord injury 
After a spinal cord injury occurs, axons are severed and multiple factors are induced or 
upregulated to prevent axonal extension from occurring such as myelin debris (1, 2), 
reactive astrocytes (3), and the lack of a growth permissive scaffold (1, 6).   
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Figure 3-2: Local paclitaxel release effect on neuronal survival 
Local paclitaxel administration does not affect neuronal viability. Isolated DRG neurons 
were cultured on tissue-culture polystyrene or PLA microfibers with various 
concentration of paclitaxel 0, 0.02%, or 0.58% for five days. Neuronal viability was 
calculated from an alamarBlue assay (C), normalized against the tissue-culture 




Figure 3-3: Effect of paclitaxel-loaded PLA fibers on RGC Extension 
Local release of paclitaxel does not affect RGC neurite extension. Retinal ganglion cells 
were differentiated from human embryonic stem cells and cultured on electrospun PLA 
microfibers with increasing concentrations of paclitaxel for 15 days. No significant 
difference in neurite extension was observed between all of the groups. Scale bar: 5 mm. 
(n = 3). 
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Figure 3-4: Isolated DRGs cultured on PTX-loaded aligned fibers 
Paclitaxel release from aligned microfibers modulates neurite extension as visualized by 
immunostaining for neurofilament. Neurite extension was quantified from isolated DRGs 
cultured on PLA fibers only (A), 0.02% PTX (B), 0.58% (C), and 3.26% (D). A small 
incorporation of paclitaxel (0.02%) promoted a significantly greater increase in neurite 
extension than fibers without paclitaxel and fibers with higher concentrations of 
paclitaxel (E). Scale bar: 100 µm. (p < 0.001, n = 6 – 10).  
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Figure 3-5: Explanted DRGs cultured on PTX-loaded aligned fibers 
Local PTX release from aligned fibers promotes DRG explant neurite extension. Neurite 
extension was quantified from DRG explants cultured on TCPS (top), PLA fibers only 
(middle image), or 0.02% PTX (bottom image). Paclitaxel incorporation in aligned 
electrospun microfibers promotes greater neurite extension than the PLA microfibers 
alone. Scale bar: 500 µm. (p < 0.05, n = 4 – 5). 
  
    * 
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Figure 3-6: Neurite extension due to release of PTX from Cell Crowns 
A local delivery of paclitaxel is needed to promote significant DRG neurite extension. 
Paclitaxel-loaded PLA microfibers were placed in CellCrown™ inserts (A) and 
suspended above cells cultured on either TCPS (B) or aligned PLA microfibers (C). A 
modest increase in neurite extension is observed when paclitaxel is released from 
paclitaxel-loaded microfibers suspended in CellCrowns™ above DRG neurons cultured 
on TCPS and PLA microfibers alone, but the maximum neurite extension only occurred 
when the cells were directly in contact with the paclitaxel-loaded microfibers (D). Scale 
bar: B–C, 40 µm. (p < 0.001, n = 7 – 10).  
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Figure 3-7: Neurite extension on various PLA surface morphologies 
The mechanism and surface topography of the local delivery of paclitaxel determines 
DRG neurite extension. DRG neurons were cultured for five days on PLA films (A) and 
randomly oriented fibers (C) that were loaded with and without paclitaxel. Although a 
slight increase in neurite extension was observed among these groups (B, D, E), 
significant neurite extension only occurred when the microfibers were aligned and 
coupled with the local release of paclitaxel (E). Scale bars: A, C, 20 µm; B, D, 100 µm. 
(p < 0.001, n = 9 – 10).  
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Figure 3-8: Effect of nocodazole administration on neurite extension 
A blocking of microtubule stabilization ablates the neurite extension from paclitaxel. To 
ensure that this paclitaxel delivery mechanism maintains neurite extension via 
microtubule stabilization nocodazole, a microtubule-destabilizing agent, was added to 
DRG neurons cultured on PLA microfibers loaded with or without paclitaxel. Once this 
microtubule stabilization is blocked, the previous axonal extension due to the local 




Figure 3-9: Isolated DRGs cultured on STB-loaded aligned fibers with 0.6% PEO 
Sunitinib incorporation in aligned PLA microfibers with 0.6% PEO promotes neurite 
extension. Isolated DRG neurons were cultured on tissue culture polystyrene or PLA 
fibers with 0.6% PEO (w/w) with increasing concentrations (0 – 0.5%) of sunitinib. As 





Figure 3-10: Isolated DRGs cultured on STB-loaded aligned fibers with 1.2% PEO  
Sunitinib incorporation in aligned PLA microfibers with 1.2% PEO promotes neurite 
extension in a concentration-dependent manner. Isolated DRG neurons were cultured on 
tissue culture polystyrene or PLA fibers with 1.2% PEO (w/w) with increasing 
concentrations (0 – 0.5%) of sunitinib. As the concentration of sunitinib increased, 
neurite extension increased in a concentration-dependent manner with neurite extension 
being greater in 0.05% STB-loaded fibers than the fibers alone or 0.5% STB-loaded 
fibers. (p < 0.05, n = 7)  
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Local Paclitaxel Release from Electrospun Fibers to Attenuate 
the Inhibitory Response Present After a Spinal Cord Injury 
 
4.1 Background 
 Under ideal growth conditions, mature central nervous system neurons can 
extend; however, after a traumatic injury occurs they cannot due to the presence of 
inhibitory components or a paucity of growth-promoting substrates [1, 2]. Therefore, an 
ideal therapeutic platform would simultaneously promote axonal extension while 
attenuating the inhibitory response present after a traumatic injury occurs. 
 
4.1.1 Glial Response to a Spinal Cord Injury 
After a spinal cord injury occurs, astrocytes are recruited to and modestly 
proliferate at the injury site and form a hallmark effect from an SCI – an astrocyte-lined 
(glial scar) cystic cavity [3, 4]. Previous research has further shown this astrocytic 
response to be inhibitory due to its prevention of axonal extension and blood vessel 
formation [5]. But recent research has shown the importance and necessity of this scar 
due to its attenuation of the inflammatory response present after the injury and 
stabilization of the injury to prevent further damage, suggesting that a balance between 
the inhibitory and growth-promoting aspect of the injury site must be balanced to 
promote maximum regeneration [6]. In fact, if these inhibitory factors are selectively 
attenuated/removed [7] or the growth-promoting factors are upregulated [8], then 
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neuronal extension can occur. 
Once astrocytes become reactive, they physically inhibit neuronal extension [9, 
10] as well as upregulate inhibitory molecules such as chondroitin-sulfate proteoglycans 
(CSPGs) that inhibit axonal extension and tissue repair [11]. CSPG upregulation is 
sustained for about eight weeks after the initial SCI with most deposition occurring in the 
first two weeks [11]. Therefore, an ideal treatment delivery system to improve spinal cord 
tissue repair should have a targeted and sustained therapeutic release for eight weeks at a 
minimum. 
 Previous methods to promote spinal cord tissue repair have focused on attenuating 
the glial and inflammatory response through cleaving the CSPGs to make them inactive 
[12], blocking the receptors on the myelin debris present after the injury [13], or 
attenuating the inflammatory response [14]. Although most treatments focus on one of 
these aspects, some of the more promising therapeutic molecules have targeted both the 
glial response and lack of neuronal extension into the injury site rather than each 
component individually [6, 15]. Paclitaxel, for instance, both promotes neurite extension 
and inhibits CSPG upregulation after an SCI [15]. However, as previously discussed, 
current paclitaxel delivery systems are limited. Aligned, electrospun PLA microfibers 
have been shown to promote neurite extension and decrease the cystic cavity volume 
after an SCI, but do not directly affect the secondary injury response [16]. As a 
combinatorial therapeutic system, paclitaxel-loaded PLA microfibers could provide a 
multifaceted platform to not only promote neurite extension (as previously shown) but 




4.2.1 Aggrecan Surface Coating 
A solution of aggrecan (200 µg/mL, Sigma-Aldrich), a type of CSPG, with 
laminin (10 µg/mL) was used to coat tissue culture polystyrene or PLA microfibers alone 
or with paclitaxel (0.02%). These protein coating concentrations were determined by 
observing neurite extension of DRG neurites after varying the concentration of aggrecan 
(50–700 µg/mL) and picking a concentration that prevented neurite extension but did not 
inhibit it. Dissociated DRG neurons were then plated at 30,000 cells/well on these coated 
and uncoated (negative control) surfaces for five days in DRG media (neurobasal media, 
5% FBS, 1% P/S, 1x GlutaMax) and then fixed with 4% paraformaldehyde (EMS). 
 
4.2.2 CSPG Spot Assay 
DRG neurons were cultured on either a laminin-coated surface, next to a CSPG 
(EMD Millipore, Billerica, MA) spot (somas present outside of the spot but neurites 
entering into the spot), or in a CSPG spots per well (somas and neurites contained within 
the spot). Prior to plating, 24-well tissue culture plates were coated with poly-L-lysine 
(PLL, Sigma-Aldrich) for one hour at 37ºC, and then washed 5 times with phosphate 
buffer solution (PBS, pH 7.4), and dried overnight. Once dried, three 1-µL spots of 
CSPGs (10 µg/mL) and Rhodamine B (1 µg/mL, Sigma) in PBS were placed onto the 
PLL-coated wells and allowed to dry overnight. Dissociated DRG neurons were then 
plated and cultured under the same conditions previously described in the Aggrecan 
Surface Coating conditions. 
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4.2.3 Astrocyte Isolation 
All astrocyte culture procedures using animals were conducted in accordance with 
protocols approved by the Institutional Animal Care and Use Committee (IACUC) at The 
Johns Hopkins University. As previously described, astrocytes were harvested and 
isolated from P0 Sprague-Dawley rat pups [17]. Cerebral cortices were isolated, 
meninges removed, separated into 4-8 pieces, and placed in Hanks’ Balanced Salt 
Solution (HBSS, Gibco). The tissue was then treated with 0.25% trypsin in HBSS for 30 
minutes at 37ºC and mechanically dissociated by trituration through a Pasteur pipette. 
Cells were then placed on poly-D-lysine (PDL, 50 µg/mL, Sigma-Aldrich) coated flasks 
and cultured for a week. Astrocytes were further isolated from other glia by vigorously 
shaking the flasks to remove non-adherent cells and further isolated for an additional two 
weeks in culture in DMEM with 10% FBS. These cells were then plated onto PDL-
coated tissue-culture polystyrene (TCPS) or random-oriented fibers with increasing 
concentrations of paclitaxel (0 – 0.25%) and maintained for 5 days in culture in DMEM 
with 10% FBS. 
 
4.2.4 Astrocyte Proliferation Assay 
Isolated astrocytes were plated at 4,000 cells/cm2 and allowed to proliferate for 
five days on TCPS, random-oriented PLA microfibers only (n = 4), PLA microfibers with 
a low concentration of paclitaxel (0.02% PTX, n = 4) or a high concentration of 
paclitaxel (0.25% PTX, n = 4) in DMEM and 10% FBS. After three days in culture, 10% 
alamarBlue® (Invitrogen, Eugene, OR) was added to each well and the fluorescence was 
quantified daily for 2 days in a Plate Reader (Biotek, Winooski, VT) at an excitation 
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wavelength of 540 nm and an emission wavelength of 590 nm. These values were 
normalized to the astrocytes grown on TCPS. 
 
4.2.5 Astrocyte CSPG Upregulation Assay 
CSPG upregulation by astrocytes was determined by plating isolated astrocytes at 
4,000 cells/cm2 and allowing them to proliferate on TCPS, random-oriented PLA 
microfibers only (n = 6), PLA microfibers with a low concentration of paclitaxel (0.02% 
PTX, n = 6) or a high concentration of paclitaxel (0.25% PTX, n = 6) in DMEM and 10% 
FBS. After five days, the cells were fixed and fluorescently labeled with an antibody 
against CSPGs (Sigma). The fluorescence of the samples was quantified in a Plate Reader 
at an excitation wavelength of 600 nm and an emission wavelength of 640 nm. 
 
4.2.6 Astrocyte Spheroid Formation and Culture 
A 3-D mold for spheroid formation was made by placing 1-milligram of sterile 
agarose in 50-milliliters of sterile saline and heated until the agarose completely dissolves. 
Once the solution cools to approximately 65ºC, 330-microliters of this solution was then 
placed in a 24-series mold (Microtissues®, Providence, RI) until the solution gels, cools, 
and separated from the molds. To form astrocyte spheroids of approximately 50 microns, 
100-µL of 2,000 cells/µL was added to each mold with 1-milliliter of astrocyte media 
(DMEM and 10% FBS) added to the outside of the molds per well in a 24-well plate. 
After these molds were placed on a shaker overnight at 200 rpm, the spheroids were 
removed by slowly pipetting media into the wells and then plating the spheroids on 
tissue-culture polystyrene, random-oriented PLA microfiber, or PLA microfibers with 
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paclitaxel (0.02% or 0.25%). 
 
4.2.7 Astrocyte Migration Assay 
Approximately five 50-µm astrocyte spheroids were placed on TCPS, random-
oriented PLA microfibers only, PLA microfibers with a low concentration of paclitaxel 
(0.02% PTX) or a high concentration of paclitaxel (0.25% PTX) in DMEM and 10% FBS 
(n = 8/group). After four days in culture, 10% alamarBlue® (Invitrogen, Eugene, OR) 
was added to each well and the fluorescence was quantified periodically for the next 24 
hours in a Plate Reader at an excitation wavelength of 540 nm and an emission 
wavelength of 590 nm.  
 
4.2.8 Immunohistochemistry 
In order to visualize the neurons, fixed cells with 4% paraformaldehyde were 
blocked in PBS-5% normal goat serum (Sigma-Aldrich) and 0.1% Triton-X (Sigma-
Aldrich) and fluorescently labeled with a chicken anti-neurofilament antibody (NF, 
1:1000, Millipore) overnight at 4ºC. Specimens were subsequently incubated for 1 h with 
goat anti-chicken Alexa Fluor® 488-conjugated secondary antibody (1:300, Life 
Technologies) and cover-slipped with Fluoroshield™ mounting medium (Sigma-Aldrich). 
For astrocytes, cells were again fixed with 4% paraformaldehyde and blocked in 
PBS-5% normal goat serum (Sigma-Aldrich) and 0.1% Triton-X (Sigma-Aldrich). They 
were subsequently fluorescently labeled with a rabbit anti-glial fibrillary acidic protein 
antibody (GFAP, 1:1000, Dako, Carpinteria, CA) overnight at 4ºC. Specimens were 
subsequently incubated for 1 h with goat anti-rabbit Alexa Fluor® 488-conjugated 
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secondary antibody (1:300, Life Technologies) and again cover-slipped with 
Fluoroshield™ mounting medium (Sigma-Aldrich). 
For visualizing CSPG upregulation, astrocytes were again fixed with 4% 
paraformaldehyde and blocked in PBS-5% normal goat serum (Sigma-Aldrich) and 0.1% 
Triton-X (Sigma-Aldrich). They were subsequently fluorescently labeled with a mouse 
anti-CSPG (1:200, Sigma) overnight at 4ºC. Specimens were subsequently incubated for 
1 h with goat anti-mouse Cy3-conjugated secondary antibody (1:300, Jackson 
ImmunoResearch, West Grove, PA) and again cover-slipped with Fluoroshield™ 
mounting medium (Sigma-Aldrich). 
 
4.2.9 Quantitative Analysis 
 Neurite extension was quantified as previously described. Additionally, neurite 
extension onto an inhibitory CSPG substrate was quantified by drawing a circle around 
the perimeter of the CSPG substrate and quantifying the neurite length inside, into, and 
outside of the CSPG spot of approximately 100 neurites/group. 
 Astrocyte spheroid diameter was quantified by measuring the diameter of 
approximately 50 astrocyte spheroids by placing a circle around the spheroid perimeter 
and quantifying the diameter using ImageJ. Furthermore, astrocyte migration was 
determined by determining the diameter of these spheres five days after initial plating on 
a TCPS surface, PLA fibers alone, or PLA fibers with low paclitaxel (0.02%) or high 
paclitaxel (0.25%) loading.  
Data are shown as mean ± standard error of the mean (SEM), and were analyzed 
using Matlab®. The experiments involving a single determination of means between two 
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independent groups were analyzed with the Student’s t-test or the one-way analysis of 
variance (ANOVA). Statistical significance was set at p < 0.05 unless otherwise noted. 
 
4.3 Results 
4.3.1 Neuronal Growth and Extension on Inhibitory Substrates 
 After an SCI occurs, inhibitory factors such as chondroitin sulfate proteoglycans 
are upregulated at the site of injury and inhibit axonal extension across the site of injury. 
Aggrecan is a CSPG that has been shown to inhibit axonal extension in vitro. Five 
hundred micrograms of aggrecan was coated on surfaces containing aligned PLA 
microfibers alone and PLA microfibers incorporated with 0.02% PTX. As expected, 
aggrecan diminished neurite extension between all DRG culture conditions tested 
compared to just laminin-coating the surface alone (Figure 3.1). However, a local release 
of paclitaxel promoted a significant increase in neurite extension than PLA microfibers 
alone under these inhibitory conditions (p < 0.001, Figure 4.1). Consequently, paclitaxel 
release from aligned microfibers promotes neurite extension in an inhibitory environment 
similar to that seen after an SCI (p < 0.005).  
Although culturing neurons on an evenly covered surface of aggrecan provides an 
initial platform to assess the effect of a local release of paclitaxel has on neuronal 
extension on an inhibitory substrate, it does not represent the conditions present after an 
SCI. Therefore, a CSPG spot assay was produced in which neurons were cultured on, 
near, or around three 1-microliter 10-µg/mL spots of CSPGs coating a surface of TCPS, 
PLA fibers alone, or paclitaxel-loaded PLA fibers (0.02%). Under these conditions, a 
local release of paclitaxel was shown to promote axonal extension into the inhibitory 
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CSPG spot compared to fibers alone or TCPS (Figure 4.2) as well as in the inhibitory 
environment as well as shown previously.  
 
4.3.2 Astrocyte Isolation and Spheroid Formation 
 In order to determine the effect of a local release of paclitaxel on the glial cell 
response after a spinal cord injury, an in vitro assay of the inhibitory environment present 
after a spinal cord injury was developed by first determining the effect of this system on 
astrocyte function. To first do this, astrocytes were effectively isolated from rat cortices 
and cultured for approximately two weeks (Figure 4.3). 
 Isolated astrocytes provided a platform to determine proliferation and viability, 
but are not as effective at quantifying astrocyte migration. Therefore a platform that 
temporarily confines the astrocytes must be established. Approximately 15-30 isolated 
astrocytes were cultured in agarose molds overnight to effectively bind together and form 
astrocyte spheroids of approximately 50 microns (Figure 4.4).  
 
4.3.3 Astrocyte Proliferation 
Once a traumatic spinal cord injury occurs, astrocytes migrate, surround the site 
of injury, and increase in activity, which results in a primarily inhibitory environment. 
Isolated astrocytes were cultured on TCPS, PLA, 0.02% PTX, or 0.25% PTX for five 
days. Using an alamarBlue® assay, astrocyte proliferation and viability were quantified. 
After three days in culture, astrocytes showed no difference in activity among the 
different groups; however, by day 4 astrocytes cultured on PLA fibers alone showed a 
significant increase in activity compared to the fibers loaded with a high concentration of 
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paclitaxel (Figure 4.5). Furthermore, after five days in culture, a local paclitaxel release 
from the PLA fibers maintained the same rate of astrocyte proliferation than the PLA 
fibers alone (p < 0.001). 
 
4.3.4 CSPG Upregulation 
Once astrocytes are recruited to the site of injury, they upregulate both growth-
promoting as well as inhibitory factors such as CSPGs that prevent axonal extension from 
occurring. Isolated astrocytes were again cultured on TCPS, PLA fibers alone, or fibers 
loaded with a low concentration (0.02%) or a high concentration of paclitaxel (0.25%). 
By fluorescently labeling the CSPGs, their upregulation was quantified and measured by 
determining the fluorescence of the CSPGs five days after initial plating of the astrocytes 
(Figure 4.6A-D). Although astrocyte reactivity remained about the same among all 
groups (Figure 4.6E), CSPG production decreased in the group with the highest 
incorporation of paclitaxel (Figure 4.6F). 
 
4.3.5 Astrocyte Migration 
 As previously discussed, after a spinal cord injury occurs astrocytes migrate to the 
site of injury physically and chemically inhibiting axonal extension from occurring. An in 
vitro assay for astrocyte migration was established by plating 50-µm diameter astrocyte 
spheroids on top of TCPS, PLA fibers alone, or fibers loaded with a low concentration 
(0.02%) or high concentration of paclitaxel (0.25%). Astrocyte diameter and migration 
rate were quantified and compared among the groups. There were no observable 
difference in the astrocyte spheroid diameter or astrocyte migration rate from the 
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astrocytes cultured on TCPS or PLA fibers alone (Figure 4.7). However, a concentration-
dependent effect was seen in that as the concentration of paclitaxel increased, astrocyte 




 Although neurite extension under a growth-conducive environment is essential for 
understanding this mechanism, it is not the environment present after an SCI. Once an 
SCI occurs, various inhibitory factors are present or upregulated that prevent axonal 
extension from occurring such as chondroitin-sulfate proteoglycans [3, 4, 11, 18]. To 
properly mimic the inhibitory effects present after a spinal cord injury, dorsal root 
ganglion neurons were cultured on an inhibitory substrate of aggrecan or CSPGs. To 
ensure that the laminin itself was also not inhibitory, we cultured the cells on an uncoated 
surface as well and observed a slight decrease in neurite extension compared to the 
laminin only group (not shown). By culturing the neurons either directly on the inhibitory 
surface (aggrecan and CSPGs) or next to the inhibitory surface (CSPGs only), we 
established that not only can a local release of paclitaxel promote neurite extension under 
an entirely inhibitory condition (aggrecan), but it can also promote neurite extension into 
the inhibitory environment as well (CSPGs). As a negative control, spots of just the 
fluorescent dye were prepared and neurons were cultured on these spots under the same 
conditions as described previously. As expected, the dye did not have an inhibitory effect 
on neurite extension (not pictured). This control group also established that the CSPGs 
were the inhibitory component in this system. We established that this platform of a local 
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release of paclitaxel can overcome an inhibitory environment and promote neurite 
extension under conditions similar to those seen after an SCI occurs. Additional testing 
that induced reactive astrocytes (i.e. through the addition of TGF-ß) could be used to 
further determine if a local release of paclitaxel attenuates astrocytes that have already 
undergone a reactive phenotype. 
As another consideration, recent studies have shown that CSPGs are not solely 
inhibitory for axonal extension in a spinal cord injury, but can also promote neuronal 
growth as well [6, 19]. Therefore further elucidating whether the growth-promoting or 
inhibitory CSPG upregulation is decreased under the conditions presented in Figure 4.6 
will need to be determined to understand the translation of this system from an in vitro 
model to an in vivo model of spinal cord tissue repair. In this study, we only performed 
one assay (immunohistochemistry) to determine if CSPG upregulation changed in 
reactive astrocytes, but future studies that quantify CSPG upregulation using rtPCR or 
Western blot assays should also be conducted. 
 Because the reactive gliosis produced after an SCI not only physically inhibits 
axonal extension, but also is necessary for axonal extension to occur, decreasing but not 
ablating astrocyte reactivity could end up promoting spinal cord tissue repair after a 
traumatic injury. Once the biological cascade is initiated after the initial physical injury, 
astrocytes migrate and proliferate forming the glial scar around the injury site. We 
showed that a local release of paclitaxel significantly attenuated astrocyte proliferation, 
migration, and inhibitory molecule production when compared to the fibers alone or cells 
cultured on TCPS. These findings further elucidate the importance of a local release of 
paclitaxel on astrocyte function. That being said, studies by Anderson et al. have shown 
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that astrocytes are essential to promoting axonal extension after an SCI [6]. Therefore, 
the inhibitory components of astrocyte reactivity must be attenuated while simultaneously 
promoting the growth-promoting aspects to optimize SCI tissue repair. Future studies will 
be needed to further understand how to initiate this system and determine the optimum 
astrocytic response for SCI tissue repair.  
 
4.5 Conclusions 
 When neurons are cultured on fibers that administer a local release of paclitaxel 
under inhibitory conditions similar to those seen after a SCI, neurite extension is 
promoted on and into an inhibitory substrate of aggrecan and CSPGs. In addition, 
astrocytes were successfully isolated from rat cortices and formed into 50-µm diameter 
spheroids to produce an in vitro model of the reactive gliosis present after an SCI. A local 
release of paclitaxel inhibited astrocytic activity (proliferation, migration, and CSPG 
upregulation). Overall, the same local release of paclitaxel from electrospun microfibers 
not only promoted neurite extension but also reduced some of the inhibitory aspects 






Figure 4-1: Neurite extension on an aggrecan surface 
A local release of paclitaxel from aligned PLA microfibers significantly promotes neurite 
extension under inhibitory conditions similar to those seen after a spinal cord injury. 
Isolated DRG neurons were cultured on an uncoated surface, laminin only, or 
laminin/aggrecan-coated tissue culture polystyrene, aligned PLA microfibers only, or 
aligned paclitaxel-loaded PLA microfibers. Paclitaxel-loaded microfibers significantly 
promoted neurite extension than PLA microfibers under both a growth-conducive 




Figure 4-2: Neurite extension onto a CSPG spot 
Local release of paclitaxel promotes neurite extension into an inhibitory substrate. 
Isolated neurons were cultured either in, near, or outside of CSPG (10 µg/mL) spots. 
These spots were placed on either TCPS (A), PLA fibers (B), or 0.02% PTX-PLA fibers 
(C). Neurite extension was significantly increased into the CSPG spot when a local 
release of paclitaxel from aligned PLA microfibers was present (D) than the fibers alone 




Figure 4-3: Astrocyte isolation 
Astrocytes were effectively isolated and cultured. Astrocytes were removed from P0 rat 
cortices and isolated after shaking and culture for 2 weeks on TCPS. Scale bar: 500 µm. 
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Figure 4-4: Astrocyte spheroid formation 
Fifty-micron astrocyte spheroids were effectively formed and cultured. After astrocytes 
were isolated from rat cortices (A), approximately 15 were placed in agarose molds to 
promote self-adhesion overnight on a shaker at 200 rpm (B). The cell spheroids were then 
plated on top of random-oriented PLA microfibers for 5 days (C). Scale bars: A: 500 µm, 




Figure 4-5: Astrocyte proliferation and survival 
Local release of paclitaxel inhibits astrocyte proliferation. Isolated astrocytes were 
cultured on TCPS, random-oriented PLA fibers, or PTX-loaded PLA fibers (0.02% or 
0.25% PTX) for five days. After three days in culture, no difference in astrocyte 
proliferation was observed among all of the groups. However by days 4 and 5 (shown as 
days 1 and 2 above), astrocyte proliferation significantly decreased in the fibers loaded 
with a low concentration of paclitaxel or both paclitaxel-loading levels, respectively. (#p 




Figure 4-6: CSPG upregulation from astrocytes 
Paclitaxel release from PLA microfibers inhibits CSPG upregulation. Isolated astrocytes 
were cultured on TCPS, PLA fibers, or paclitaxel-loaded PLA fibers (0.02% or 0.25% 
PTX) for five days (A-D). After fluorescently labeling astrocytes (green) and CSPGs 
(red), relative fluorescence intensity was quantified for each sample using a Plate Reader. 
Astrocyte reactivity slightly decreased among the groups loaded with paclitaxel (E), but 
most noticeably CSPG production decreased if paclitaxel was released from PLA fibers 
(F). Scale bar: 200 µm. (*p < 0.05, **p < 0.01, n = 6).  
80 
 
Figure 4-7: Astrocyte migration 
Local release of paclitaxel inhibits astrocyte migration. Fifty-micron astrocyte spheroids 
were cultured on TCPS, PLA fibers, or paclitaxel-loaded PLA fibers (0.02% or 0.25%, 
A-D). After five days in culture, spheroid diameter was quantified for each group. By 
incorporating paclitaxel in PLA fibers, astrocyte migration speed significantly decreased 
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The In Vivo Response to Paclitaxel Administration from 
Electrospun PLA Microfibers 
 
5.1 Background 
 Although in vitro studies are necessary to further elucidate the processes and 
pathways present after a spinal cord injury is induced, this controlled environment does 
not accurately portray the entire injury and repair system present after an SCI. Most 
notably, the inflammatory response after an SCI is extremely complex and still not 
completely understood, which makes it hard to model in vitro [1]. In fact, multiple 
potential therapies for spinal cord injury applications showed promising results in vitro, 
but when tested in vivo saw limited functional recovery improvements [2, 3]. 
Consequently, in vivo animal models are necessary to advance therapeutic interventions 
to potential human clinical applications. 
 
5.1.1 SCI Injury Models 
 Although ideally clinical testing in humans would be preferred to optimize 
therapeutic interventions, due to FDA safety and efficacy regulations animal models must 
be initially developed and used. For spinal cord injury animal models specifically, many 
animal models have been used from mice to non-human primates, but a majority of the 
studies in the past ten years (88%) have involved rodents [4]. Rats, specifically, are more 
advantageous to use in SCI models than mice due to their larger size (advantageous for 
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treatment implantation and observing behavioral recovery) and more similar scar 
formation to humans than mice [5]. 
 In addition, there are multiple injury models of a spinal cord injury that are 
commonly used, such as contusion, compression, and transection models [6]. For a 
contusion injury, a transient or acute injury impacts the spinal cord. A contusion is a 
clinically-relevant model and can be induced through an impactor or weight-drop 
apparatus. Some of the primary issues with the contusion model are that there can be a 
large variability per injury and some of the impactors have issues with supporting the 
animal [6, 7]. 
Unlike a contusion injury, in a compression injury a device squeezes the spinal 
cord with a specific force for a more extended duration to induce an SCI [8]. Clinically 
this type of injury occurs due to a fracture dislocation in which a bone constantly impacts 
the spinal cord until it is removed. This injury model can be induced via clips, forceps, or 
even balloons and is advantageous in understanding the effect of a loss of blood flow 
while keeping the surrounding tissue intact. However, some of these models don’t induce 
the acute injury commonly present in a spinal cord injury and have some issues with 
repetition as well [6].  
 In a transection spinal cord injury, the spinal cord is either partially or completely 
severed at a particular level by severing the tissue with a scalpel. Although this model 
does not represent the injuries most common after a spinal cord injury, they do present 
the opportune model to determine the axonal extension and tissue repair due to a 
therapeutic intervention [6, 9]. That being said, a complete transection injury model is 
much more severe to the animal and makes behavioral recovery hard to measure and 
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track. In a partial transection model (also referred to a hemisection in some cases), the 
behavioral improvements are easier to assess, but it can be more difficult to induce a 
consistent injury over time. One example of a partial transection injury is the dorsal 
column transection model in which a section of the dorsal column is surgically removed 
from the spinal cord, resulting primarily in loss of sensory function (severing of the 
ascending tracts and inadvertently some descending tracts as well) below the site of 
injury (Figure 5.1). 
 Even though each injury system has its advantages and disadvantages, the partial 
transection system is ideal for an initial assessment of biomaterials efficacy due to its 
similarities to clinically induced injuries, ease of determining novel axonal growth and 




5.2.1 Conduit Assembly  
 Aligned PLA fibers were produced as mentioned previously onto a PLA film-
covered 20-µm x 20-µm coverslip. Two sheets of these fibers were then peeled from the 
coverslips and placed back-to-back and rolled into conduits (Figure 5.1). By folding the 
conduit in an S-shape, a middle insert was created within the conduit lumen to increase 
the surface area for cell-substrate interactions and to decrease the probability of tube 
collapse. Prior to usage in animal models, samples were sterilized using an ethylene 
oxide sterilizer for a 12-hour cycle.  
 
86 
5.2.2 Dorsal Column Transection Spinal Cord Injury Model 
Animals 
Ten-week old Female Sprague-Dawley rats (strain 400, 180-200 g, Charles River) 
were housed according to NIH and USDA guidelines within the double-barrier facility of 
the Miami Project to Cure Paralysis. 
 
Pre-Surgery Preparation 
Before surgery, rats were anesthetized with an intraperitoneal injection of 
Ketaset® (ketamine, 75 mg/kg, i.p.) and Dexdomitor® (dexmedetomidine, 0.5 mg/kg, i.p.) 
which is consistent with recommendations of the Panel on Euthanasia of the American 
Veterinary Medical Association [10, 11]. An adequate level of anesthesia was determined 
by monitoring the absence of corneal reflexes and hindlimb withdrawal to an otherwise 
painful stimulus. Then, the back of the rats was shaved and aseptically prepared using 
Betadine. Lacri-Lube ointment was applied to the eyes to prevent drying while under 
anesthesia. Rats were kept on a regulatable heating pad set at 37 ± 0.5ºC during surgical 
procedures to maintain their body temperature constant. 
 
Injury Paradigm 
From anaesthetized rats, the back over the mid/low thoracic (T) level of the spinal 
column was incised, the back muscles retracted to expose the spinal column, and the 
dorsal aspect of the T8 vertebra was removed without damaging the dura mater to expose 
the underlying T9 spinal cord [10, 11]. Next, with surgical microscissors, the dura was 
opened without damaging the exposed spinal cord and a longitudinal rectangular shaped 
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gap (2 mm long and 1 mm wide) was created in the dorsal column [12, 13]. If needed, 
gelfoam was gently applied to stop bleedings within the lesion gap. After bleeding had 
stopped, the lesion gap was dried and the material (either PLA fiber bundle or PLA fiber 
scaffold) implanted. The material was kept in saline during the surgical procedures and 
cut in the appropriate length to cross the lesion gap and oppose the rostral and caudal 
spinal cord. Then, the exposed area was rinsed with 0.1 % gentamicin in PBS (0.1 M, pH 
7.4), the back muscles were closed in layers with 4.0 Ethicon sutures, and the skin was 
closed with metal wound clips. 
 
Pilot Study 
For the short-term pilot study, rats (n = 18) were randomly divided into 4 groups 
and implanted with gel foam (n = 3), aligned PLA fibers (n = 5), a low concentration 
paclitaxel-loaded PLA fibers (0.02% PTX, n = 5), or a high concentration of paclitaxel-




Two experimental groups (n = 60) received PLA microfiber bundles (that were 
prepared as described previously) with or without (control) PTX. Each of the two groups 
consisted of 15 rats that were used for anatomical assessments only (survival 2, 4, and 8 
weeks, n = 5/group) and 15 rats that were used for functional assessments at 2, 4, 6, and 8 




Rats receive Antisedan® (1 mg/kg; intramuscular) to reverse the anesthesia and 
lactated Ringers’ solution (10 ml, subcutaneous) to replenish electrolytes/fluids [10, 11, 
14]. Rats were kept in an incubator at 37°C and monitored continuously until awake 
before they were returned to their cages. To prevent possible infections rats were treated 
subcutaneously with gentamicin (6 mg/kg body weight) daily during the first week post-
surgery [10, 11, 14]. Rats received buprenorphine (0.03 mg/kg body weight; Sigma) 
subcutaneously twice a day (every 12 h) for 3 days post-injury/implantation [10, 11]. The 
general health of the rats was evaluated by direct observations by professional caretakers 
twice daily during the first week and once daily thereafter. Rats were kept clean on a 
daily basis if needed and monitored for urine scalding. If necessary they were treated 
with anti-scalding ointment. Water and food were available ad libitum throughout 
survival. The bladder was manually emptied manually twice a day until no longer needed. 
The metal skin wound clips were removed after 7 days. If pain or distress occurred during 
survival, we treated the rats subcutaneously with buprenorphine (0.03 mg/kg body 
weight; Sigma). 
 
5.2.3 Behavioral Response and Observation 
Rats were tested for changes in hind limb motor/sensorimotor and sensory 
function for up to 8 weeks after lesion/implantation [10, 11]. With our lesion paradigm, 
rats perform the proposed functional tests without problems other than the inflicted 
impairment. For overground walking, we used the 21-point BBB open field locomotor 
test specifically designed to evaluate automated hind limb function after spinal cord 
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contusion [15, 16]. This test distinguishes between movements of individual joints of the 
hind limbs. Complete paralysis scores a ‘1’ and normal walking scores a ‘21’. All rats 
that needed to perform the BBB test were in the open field and their performance scored 
twice a week for 2 weeks before being subjected to injury and implantation. This 
provided baseline values and allowed the rats to adapt to the testing environment. During 
survival, 2 examiners oblivious of the treatments were located at a constant position 
relevant to the open field and performed the tests over a period of 4 min weekly until 
termination of the experiment. For higher motor functions we used the BBB subscore [10, 
11, 17]. In the predominant paw, weekly the position [internal/external at initial contact 
(IC) and liftoff (0 points), parallel at IC and internal/external at liftoff or vice versa (1), 
parallel at IC and liftoff (2)], toe clearance [none (0), occasional (1), frequent (2), 
consistent (3)], tail position [down (0), up (1)), and trunk stability (no (0), yes (1)] were 
determined. Scores are summed for a maximum score of 7. 
Sensorimotor function was evaluated using the horizontal ladder-walking test [10, 
11, 18]. Walking over the horizontal ladder requires integration of sensory and 
descending information to control proper (hind) paw placement and weight support. We 
tested the rats on the ladder at 2, 4, 6, and 8 weeks post-injury/implantation. A 100 cm 
long custom-made (horizontal) ladder was used which the rats walked across 3 times 
each test. Every passage was videotaped to enable accurate evaluation of the 
performances. Only the middle 60 cm of the ladder was used for measurements. Small 
(foot or part of foot), medium (foot and part of lower leg), and large (full leg) slips were 
counted and were expressed as a percentage of the total number of steps. The test was 
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performed before injury to determine normal baseline values, just before 
injury/implantation and at 4 and 6 weeks post-treatment. 
Sensory function was assessed using mechanical allodynia (i.e., a pain-related 
response to a normally innocuous stimulus), which was measured at 3 and 6 post-
injury/implantation by assessing the force to the hind paw resulting in limb withdrawal 
[19]. Rats were acclimated for 5 min before measurements in a Plexiglas test box with an 
elevated mesh floor. An electronic von Frey anesthesiometer was applied perpendicularly 
to the mid-plantar area of each hind paw and the pressure increased until limb withdrawal. 
The force (in g) at withdrawal was recorded. Three middle measurements out of five of 
each paw were averaged. Baseline values were determined before injury/implantation.  
 
5.2.4 Tissue Processing 
Rats were anaesthetized with Ketaset® (100 mg/kg, i.p.), injected with 0.5 mL 
heparin (heparin sodium, 1000 units/mL) in the heart, and perfused transcardially with 
300 ml saline (room temperature) to rinse out the blood and 500 ml of 4 % 
paraformaldehyde in PBS (0.1M, pH 7.4) [10, 11]. This procedure fixes the spinal cord 
for harvesting and processing for histology. The spinal cord was dissected out and post-
fixed in the same fixative overnight at 4ºC before being transferred to 30% sucrose in 
PBS (0.1M, pH 7.4) for at least 24 hours. Then, a 2 cm long segment of the spinal cord 
centered at the dorsal column lesion was cut on a cryostat in 10 series of 20 µm thick 
sagittal sections, which were mounted on positively charged microscope slides. For 
immunostaining, non-specific binding sites were blocked using 0.01M PBS (pH 7.4) with 
5% Normal Goat Serum (NGS) and 0.03% Triton blocking solution at room temperature 
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for 1 hour. Sections were immunostained with antibodies against neurofilament to 
recognize axons, GFAP to recognize astrocytes, and NeuN to recognize neurons. All 
incubations with primary antibodies were overnight at 4ºC. Then, sections were rinsed, 
incubated at room temperature for 2 hours with secondary antibodies conjugated with 
fluorescent markers, rinsed, DAPI counterstained, and finally covering with a glass slip 
using anti-fade fluorescent mounting media (Dako, #S3023). One series of sections was 
stained with cresyl violet to identify neurons. 
 
5.2.5 Quantification and Data Analysis 
Tissue sample metrics were completed using the StereoInvestigator software 
(MicroBrightField Inc., Colchester, VT). For neurofilament, the counting frame was 
started at a randomized first section and then the inclusion criteria included a NF of 
minimum length of 5 µm, inclusion in the boundaries set by StereoInvestigator, and in 
order to minimize error due to irregular slicing NF location within 1 µm of the set z-axis. 
Outlining of the serial sections was conducted by a single investigator naïve to the 
treatment group. The total approximation by optical fractionator and the second 
coefficient of error were calculated as estimates and a value of 0.1 for the second 
coefficient of error was accepted. Using StereoInvestigator, relative fluorescence 
intensity and tissue volume were also calculated with tissue labeled with antibodies 






 5.3.1 Microfiber Conduit Assembly 
 PLA microfiber conduits were assembled by wrapping two electrospun of PLA 
microfiber sheets (20 mm x 20 mm) into an S-shaped conduit (Figure 5.2) similar to 
previous methods by Hurtado et al. [20]. This conduit was approximately 1.7 mm in 
diameter and ranged in length based on the size of the injury for implantation (1-2 mm). 
Previous studies have show that the formation of the conduit did not affect fiber 
alignment and provided an adequate platform to promote spinal cord tissue repair after an 
SCI [20].  
 
5.3.2 Pilot Study (Conduit) 
 Shortly after production, PLA S-shaped conduits with increasing concentrations 
of paclitaxel (0, 0.02, 0.25%, or 3.26%) were disinfected by ethylene oxide sterilization 
and implanted into a dorsal column transection spinal cord injury. Two weeks after 
implantation, the animals were euthanized, tissue fixed, and samples labeled for astrocyte 
markers and neuronal markers. 
 After an SCI occurs, a large, complex inflammatory response is induced that 
prevents axonal and blood vessel infiltration into the site of injury [1]. Two weeks after 
implantation of paclitaxel-loaded fibers, tissue cavitation and sparing was quantified by 
staining the samples with the cresyl violet stain and processing them with the Cavalieri 
method of segmentation with point-counting from spinal cord cross-sections in 
StereoInvestigator. By quantifying the tissue present around the injury, we determined 
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that a local release of paclitaxel did not promote or exacerbate tissue cavitation after an 
SCI (Figure 5.3). 
In a second set of serial sections, immunohistochemistry analysis with an 
antibody against glial fibrillary acidic protein (GFAP) was conducted. Figure 5.4 shows 
some representative micrographs depicting a cross-section of rat spinal cord at the 
epicenter of the lesion stained for GFAP (Figure 5.4A and B). Quantification of GFAP-
reactivity with relative fluorescence intensity showed that the administration of a local 
release of paclitaxel from aligned PLA fibers significantly inhibited reactive gliosis 
starting two weeks after conduit implantation (Figure 5.4C). 
 Once we determined that reactive gliosis was attenuated, we wanted to determine 
the effect of a local release of paclitaxel on neurite extension into the conduit. Cross-
sections of the conduit in the epicenter of the lesion were removed and fluorescently 
labeled against the Neurofilament (NF) antibody (Figure 5.5A and B). The number of 
axons within each conduit was determined by counting the number of axons within the 
section. By completing this quantification, we determined that a local release of 
paclitaxel does not have a direct effect on axonal extension under these conditions 
(Figure 5.5C). 
 
5.3.3 Long-Term Study (Bundles) 
After determining that administering a local release of paclitaxel from aligned 
PLA microfibers promote spinal cord tissue repair, PLA fiber bundles were produced as 
previously mentioned with a diameter of approximately 1 mm – twisting the fiber 
bundles tighter or looser to modify the diameter – and length based on the size of the 
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injury (0.5-1 mm). Shortly after production, these bundles were then implanted for six 
weeks in animals that received a dorsal column transection. After six weeks in situ, these 
bundles were successfully implanted in the injury site, integrated with the host tissue, and 
modestly aligned with the direction of the spinal cord as well (Figure 5.6).  
 Six weeks after injury and implantation of gel foam, PLA microfiber bundles only, 
or PLA microfiber bundles loaded with 0.25% PTX, locomotor and sensory behavioral 
analysis was conducted. To determine locomotor recovery, the BBB test was performed 
and quantified six weeks after injury (Figure 5.7A). As shown in Figure 5.7B, a local 
release of paclitaxel did not improve locomotor function than PLA fibers alone. 
Additionally, after a spinal cord injury occurs, sensory deprivation and an 
increase in pain sensation occur at targets below the site of injury. In order to quantify 
this in vivo, mechanical allodynia was evaluated using an electronic von Frey 
anesthesiometer – Figure 5.8A shows the mechanical von Frey filaments. No decrease in 
mechanical threshold was observed between the groups with or without paclitaxel-loaded 
fiber bundles suggesting no allodynia was induced (Figure 5.8B). 
 
5.4 Discussion 
Even though the original S-shaped conduit design showed preliminary promise in 
spinal cord injury tissue repair, the diameter of the conduit was not ideal for the injury 
model used. For a rat dorsal column injury, the diameter of the injury can range from 
0.5–1 mm, whereas the smallest diameter capable of being produced in this conduit is 
approximately 1.5 mm– in our case it was approximately 1.7 mm. Previous research 
using this material conduit involved a complete transection injury, which required a 
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conduit with a much larger diameter (1.5 mm–3 mm). Therefore, a smaller diameter 
conduit design was necessary to continue using the dorsal column transection model for 
spinal cord injury. Although axonal extension into the scaffold remained the same for all 
paclitaxel-loading levels, this could be attributed to not enough time for the neurons to 
extend into the middle of the scaffold or insufficient adherence of the neurons to the 
fibers, which would prevent the previous effect seen in vitro that a local release of 
paclitaxel is necessary to promote neurite extension from occurring. For the pilot study, 
no control group of PLA fibers only was used solely to determine which paclitaxel 
loading level should be used in subsequent long-term studies. From the promising results 
seen in the pilot study with regards to the effects of a local release of paclitaxel 
decreasing reactive gliosis and not inhibiting axonal extension, the middle concentration 
loading of paclitaxel (0.25%) was chosen for subsequent long-term in vivo studies.  
Following a spinal cord injury, a loss of motor function and sensory sensation 
occurs below the site of injury. After a six-week implantation of PLA microfiber bundles 
loaded without or with 0.25% paclitaxel, behavioral recovery and pain stimulation were 
monitored and quantified. Due to the complexity and long-term recovery after a spinal 
cord injury, these functions were monitored under the longer durations and varying 
conditions of this study. Although no locomotor recovery was observed after six weeks of 
implantation, further analysis of axonal extension into the fibers and a longer duration of 
implantation (8+ weeks) may be necessary to further determine the effects of this 
treatment on spinal cord tissue repair. Although no locomotor recovery was observed, 
limited locomotor was expected due to the severity and location of the injury in the dorsal 
column of the rat spinal cord. 
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Furthermore, paclitaxel administration has been shown to induce peripheral 
neuropathic pain [21]. Because axonal sprouting has been shown to induce neuropathic 
pain and paclitaxel modulates neuronal sprouting, an effect of a paclitaxel administration 
on pain induction in a rat model of spinal cord injury was quantified [22, 23]. Specifically, 
mechanical allodynia was quantified six weeks after injury. After this duration it was 
determined that a local release of paclitaxel did not induce allodynia compared to the 
control group of just PLA microfibers alone. 
 
5.5 Conclusions 
 In these studies, we successfully produced two varieties of growth-promoting 
scaffolds for spinal cord injury repair, an S-shaped conduit and a PLA fiber bundle that 
were then implanted into a dorsal column transection injury for 2 or 6 weeks, respectively. 
The paclitaxel-loaded S-shaped conduit provided an opportune platform to maintain 
tissue sparing, inhibit reactive gliosis, and support axonal extension. Furthermore, the 
PLA fiber bundle loaded with paclitaxel had a limited effect on locomotor recovery, but 





Figure 5-1: Dorsal column transection model injury 
The dorsal column transection injury primarily involves slicing or removing an 




Figure 5-2: PLA microfiber scaffold and preparation 
Electrospun PLA microfiber conduits were successfully constructed and assembled. A 
fiber square (20 mm x 20 mm) mesh (A) was wrapped (B) and glued together with a PLA 
solution to form an S-shaped conduit (C). Fiber conduits of approximately 1.7 mm 
diameters were developed and coated with an exterior random fiber mesh (D, E). Scale 




Figure 5-3: Pilot study – Tissue sparing 
Local release of paclitaxel does not promote tissue cavitation. Rats were given a dorsal 
column transection injury and implanted with either gel foam or PLA fibers loaded with 
0.02% (A), 0.25% (B), or 3.26% (C) paclitaxel. Spinal cord cross-sections were fixed and 
labeled with a cresyl violet stain. After two weeks of implantation, no significant 
difference was observed in tissue sparing when the paclitaxel-loaded fibers were 




Figure 5-4: Pilot study – Glial response 
Local release of paclitaxel inhibits reactive gliosis. Rats were given a dorsal column 
transection injury and implanted with either gel foam (A) or PLA fibers loaded with 
0.02%, 0.25%, or 3.26% (B) paclitaxel. Spinal cord cross-sections were fixed and 
fluorescently labeled for astrocytes with a GFAP antibody. After two weeks of 
implantation, a local release of paclitaxel from aligned PLA microfibers promoted a 
concentration-dependent decrease in reactive gliosis production (C). Scale bar: 500 µm. 




Figure 5-5: Pilot study – Axonal extension 
Local release of paclitaxel does not affect axonal extension. Rats were given a dorsal 
column transection injury and implanted with either gel foam (A) or PLA fibers loaded 
with 0.02%, 0.25%, or 3.26% (B) paclitaxel. Spinal cord cross-sections were fixed and 
fluorescently labeled for neurons with a neurofilament antibody. After two weeks of 
implantation, a local release of paclitaxel from aligned PLA microfibers had no effect on 




Figure 5-6: Long-term study – Fiber incorporation 6 wpi 
Fibers incorporate with spinal cord tissue. Rats were given a dorsal column transection 
injury and implanted with PLA bundles loaded with or without paclitaxel. Implanted 
fibers successfully integrated with native tissue and moderately maintained their 




Figure 5-7: Long-term study – Locomotor recovery 
Local release of paclitaxel from aligned PLA fibers does not effect locomotor recovery. 
Hind limb locomotor function was evaluated in the open field and scored using the BBB 
test (A). Post-SCI evaluation was quantified 6 weeks post-injury. There was no difference 
in locomotor recovery in animals receiving a local release of paclitaxel than animals with 
only the PLA microfiber bundles (B). (n = 14 – 15).  
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Figure 5-8: Long-term study – Sensory response 
Local release of paclitaxel from aligned PLA fibers does not induce mechanical allodynia. 
A non-noxious light touch of the plantar surface of the paw with von Frey filaments was 
used to assess hind limb sensation and mechanical allodynia (A). The withdrawal 
threshold in response to mechanical stimulation was quantified. Post-SCI evaluation was 
quantified 6 weeks post-injury. A local release of paclitaxel did not exacerbate the 
mechanical allodynia present from the PLA microfiber bundles alone (B). (n = 14 – 15).  
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Discussion and Conclusions 
 
6.1 Novelty and Significance 
Throughout this study, we have demonstrated that microtubule-stabilizing agents 
(such as paclitaxel) can be successfully incorporated into electrospun PLA microfibers. 
Furthermore, this incorporation method releases these molecules constantly over a 12-
week period, promotes axonal extension in vitro, and inhibits reactive gliosis in vivo. 
 Although our study is not the first to incorporate paclitaxel in electrospun fibers, it 
is the first to use this platform to be developed for spinal cord tissue repair. In this system, 
we controlled the continuous release of paclitaxel for up to 4 weeks longer than previous 
studies have already shown [1]. In animal studies, this delivery mechanism does not 
induce neuropathic pain, which could be a concern with paclitaxel delivery. Interestingly, 
this study is not only the first to incorporate sunitinib in electrospun fibers, but also 
discovered that sunitinib has an effect on neuronal extension. 
 
6.2 Implications 
There are currently no FDA-approved treatments to promote spinal cord tissue 
repair after a traumatic SCI. This study advanced the understanding of how a local drug 
delivery system coupled with an aligned contact guidance can affect axonal growth and 
ultimately spinal cord tissue repair. One main advantage of this system is that it is not 
limited to one drug or treatment, which broadens its possible treatment indications 
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outside of traumatic nerve regeneration alone. Other aligned tissue engineering 
applications, such as muscle regeneration, could also benefit from this study’s findings. 
In order to establish this system, we first wanted to determine if the release of 
paclitaxel from electrospun microfibers could be modified and controlled. To do this, we 
varied the amount of paclitaxel that we loaded into the PLA polymer solution and 
measured paclitaxel release from these fibers over 12 weeks and found that due to the 
slow diffusion of paclitaxel from these microfibers, larger incorporations of paclitaxel in 
the fibers promoted a faster and larger release. This timeline is ideal for spinal cord tissue 
therapeutic applications due to the scar formation occurring within the first few 
weeks/months after the injury occurs [2]. In addition, modifying the fiber density can also 
modify the amount of released paclitaxel as well as provide a more uniform growth 
conduit for axons to grow on as well. These findings are necessary to modify this 
platform for future animal models of SCI and translational applications.  
 Previous approaches of paclitaxel administration for anti-cancer treatments have 
involved osmotic mini-pumps, hydrogels, and nanoparticles [3-5], which can be difficult 
to administer for a long duration in humans. However, electrospun microfibers provide a 
unique platform for spinal cord injury applications due to their lack of necessity to 
incorporate paclitaxel in a neuropathic solvent, directed growth-permissive scaffold to 
promote axonal extension across the injury site, biodegradable platform, and long-term 
treatment release. A low concentration administration of paclitaxel has previously been 
shown to promote neurite extension [3, 6]. By incorporating paclitaxel into aligned 
microfibers, neurons receive a controlled, low concentration dosage of paclitaxel that, 
when coupled with a growth-permissive scaffold, promoted axonal extension by 
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stabilizing microtubule formation. Furthermore, other therapeutic applications that 
require a localized treatment delivery, such as anticancer or antibiotic delivery, could 
leverage the advantages of this platform to maximize potency and limit the adverse 




One of the most pertinent issues of this novel platform with regards to 
translatability is that incorporating paclitaxel in aligned fibers for spinal cord injury 
applications can no longer be patented. Due to this issue, it is very unlikely that a 
pharmaceutical company will be willing to invest the time and money to scale this 
platform for patient usage. That being said, other novel microtubule-stabilizing 
therapeutics such as sunitinib and epothilone B [8] could instead be incorporated.  
As another consideration for translation, this platform will require a surgical 
intervention for implantation –likely days-weeks after the initial injury to assess and 
characterize the injury severity. This platform has only been tested in an acute injury and 
will need to be further tested to determine its effects on a chronic (months-years after the 
initial injury) spinal cord injury, which make up greater than 90% of current patients with 
a spinal cord injury. 
Finally, the injury paradigm tested requires a spinal cord injury that severs or 
removes a large portion of the spinal cord to be effective, whereas in most real-world 
SCIs a contusion is more prevalent [9]. Therefore, this platform will need to be adapted 
for these systems, which it can easily be modified by simply placing a sheet of the 
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paclitaxel-loaded fibers on top of the spinal cord rather than implanting them directly into 
the spinal cord similar to previous treatment applications [10]. 
 
6.3.2 Material 
One of the biggest concerns of using PLA for medical applications is the 
toxicity of its degradation byproducts [11]. Due to previous in vivo testing with PLA 
products, we do not believe that this platform should develop a high enough 
concentration of PLA to produce a toxic environment for spinal cord tissue repair, but 
subsequent testing will monitor these degradation products to prevent this from 
becoming an issue. 
As previously mentioned a surgical intervention would be necessary to 
introduce this platform, which could expose the patient to unnecessary infections and 
complications. Therefore, this system would need to be adapted to mitigate these 
issues, potentially by incorporating the paclitaxel in self-assembling PLA block 
copolymers [12] that could then be injected into the injury site rather than implanted. 
As an additional consideration, NatureWorks LLC has recently determined that 
their commercially available polylactic acid can no longer be used in medical device 
testing due to safety concerns. Therefore, a new supply of FDA-approved PLA would 
need to eventually be sourced for future safety and efficacy testing applications. 
 Under in vitro conditions, paclitaxel release was quantified through a diffusion-
based system. However, in the in vivo studies, this release was not quantified. Due to the 
complex biological response that occurs after a spinal cord injury, the paclitaxel may not 
have released at the same rate as previously determined, which could explain some of the 
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limited results observed. The remaining paclitaxel in the fibers, and in turn the 
concentration of paclitaxel released, could be quantified in future tests similar to the UV-
Vis Spectroscopy methods mentioned previously. 
 
6.3.3 Cellular 
Although we preliminarily looked at the mechanism driving axonal extension in 
this system, with nocodazole administration, more than likely there are multiple pathways 
acting on microtubule formation in this system. For instance, paclitaxel, like most other 
lipophilic drugs, is uptaken by cells through a passive diffusion process via transcellular 
transport across the cellular membrane. Because of the potency effect that we observed 
from a local paclitaxel administration on axonal extension, we hypothesize that different 
uptake mechanisms could be driving this system. For instance, paclitaxel may not fully 
incorporate in the media and instead be directly uptaken by the cell, which would require 
a smaller, local concentration to be effective. Considering the strong synergistic effect 
seen in this system from the local release of paclitaxel and the aligned fibers, there is 
probably a convergence of multiple pathways that drives the axonal extension that future 
studies would need to further elucidate. 
Despite the fact that neuronal survival assays were conducted in vitro, limited 
axonal extension occurred in vivo. Future studies will further clarify whether apoptosis is 
also being affected in this in vitro assay and if any of this could explain the limited 
axonal extension into the conduit two weeks after implantation. One of the most likely 
reasons is that there was not enough time for the axons to grow into the center of the 
conduit. Another reason could be what is known as the “candy store effect” in which an 
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ideal environment (the scaffold itself) does not incentivize the axons to leave and 
reinnervate with other target, downstream axons. Introducing a paclitaxel concentration 
gradient in subsequent studies could help alleviate these issues. 
 
6.4 Future Directions 
Recent tissue engineering applications have utilized the necessity of cellular 
incorporations, especially pluripotent stem cells, with materials to better simulate a 3-
dimensional environment as well as better promote autologous tissue regeneration after 
implantation [13]. That being said, this system will need to undergo a long regulatory 
process once cells are incorporated, especially considering that stem cell differentiation 
has not been fully optimized. 
 There have been a large amount of therapies and materials used for spinal cord 
tissue regeneration applications [10, 14, 15], but most have had limited functional 
improvements after administration. Some of the most promising in the past have involved 
combinational therapeutics that target multiple inhibitory components of a spinal cord 
injury to promote axonal regeneration [16]. As previously mentioned, self-assembling 
molecules other than PLA could also be used to incorporate and deliver paclitaxel for 
spinal cord injury applications to prevent the need for a surgery and potential for 
additional complications [17]. 
Incorporating drugs that block other inhibitory substrates present at the site of 
injury, such as NEP1-40 for myelin fragments, with paclitaxel in the fibers could further 
promote autologous cellular regeneration and ultimately spinal cord tissue repair. As 
more pathways associated with axonal growth continue to be discovered, new therapeutic 
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applications, such as inhibiting the phosphatase and tensin homolog (PTEN) pathway, 
could be also be targeted [18]. 
 
6.5 Conclusions 
These studies have established the necessity of a local release of a therapeutic 
molecule that must be delivered within a narrow concentration range to prevent adverse 
effects while also promoting tissue regeneration. Furthermore, these therapeutic 
molecules can be incorporated into electrospun PLA microfibers and released at a 
controlled rate over an extended period of time (12 weeks+). Most important for spinal 
cord tissue repair, this system effectively promoted neurite extension while also 
inhibiting astrocyte function in an in vitro and in vivo model of SCI. Even after a long-
term administration of paclitaxel in vivo, neuropathic pain is not stimulated. Most 
importantly, this system provides a platform that could promote tissue engineering among 
multiple systems (e.g. muscle regeneration) throughout the body and has implications in 
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